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Abstract 
 
The ability of the Generalised AMBER Force Field (GAFF) to model the structure of 
bisphosphonate ligands, C(R1)(R2)(PO32-)2, important compounds in the treatment of bone 
cancer, by molecular mechanics methods is evaluated.  The structures of fifty bisphosphonates 
and nine bisphosphonate esters were predicted and compared with their crystal structures.  Partial 
charges were assigned from a RHF/6-31G* single point calculation at the geometry of the crystal 
structure.  Additional parameters required for GAFF were determined using the methods of the 
force field’s developers.  The structures were found to be well replicated with virtually all bond 
lengths reproduced to within 0.015 Å (1.2σ).  Bond angles were reproduced to within 1.9o (0.8σ).  
The observed gauche or anti conformation of the molecules was reproduced, although in several 
instances gauche conformations observed in the solid state energy-minimised into anti 
conformations, and vice versa.  The interaction of MDP (R1 = R2 = H), HEDP (R1 = OH, R2 = 
CH3), APD (R1 = OH, R2 = (CH2)2NH3+), alendronate (R1 = OH, R2 = (CH2)3NH3+) and 
neridronate (R1 = OH, R2 = (CH2)5NH3+) with the (001), (010) and (100) faces of hydroxyapatite 
was examined by energy-minimising twenty random orientations of each ligand 20 Å from the 
mineral and then at about 8 Å from the surface whereupon the ligand relaxes onto the surface.  
The difference in energy between the two systems is the interaction energy.  In all cases 
interaction with hydroxyapatite caused a decrease in energy.  On the (001) face, both 
phosphonate groups interact near a surface Ca2+ ion. The magnitude of the exothermic interaction 
energy varies with molecular volume (MDP < HEDP < APD < alendronate) except for 
neridronate, which interacts less effectively than alendronate because the long amino side chain 
folds in on itself and does not align with the surface of the mineral.  The bisphosphonates adopt 
two conformations on the (010) face.  In the first of these, found for MDP and 40% of the 
alendronate structures, both phosphonates interact with the surface and the side chain points 
away from the surface.  In the second conformation, one phosphonate and the Cα side chain 
interact with the surface.  The interaction energy increases with the molecular volume of the 
ligand, again with the exception of neridronate.   Two conformations also occur on the (100) 
face.  In the first conformation, only one of the phosphonate groups points towards the surface 
and the Cα side chain interacts with the surface; in the second conformation the Cα side chain 
interacts strongly with the surface and both phosphonate groups point away from the surface 
towards the solution.  The first conformation is energetically more favourable.  Its magnitude is 
  
 
 
virtually insensitive to the nature of the side chain and is similar to the magnitude of the 
interaction energy on the other two faces.  The magnitude of the second conformation increases 
with the size of the Cα side chain.  
Acknowledgements 
 
I would just like to thank a few people who without their assistance this project would not have 
been possible. 
 
Firstly I would like to thank Professor Helder Marques for all his valuable assistance and 
guidance over the last few years.  Professor Marques has always been available to assist and 
patiently explain the science of the research (often repeatedly) to me.  Thank you for always 
being so open and willing to share your expertise with me.  He has been extremely supportive 
and I am really grateful.   
 
Secondly I would like to thank Dr. Alvaro De Sousa who assisted with various aspects of this 
project. 
 
Thank you to Manuel Fernandes and Professor Dave Billing who were always available to assist 
with any queries in connection with crystallographic structures or modelling.   
 
Finally I would like to thank Agnes for always assisting with the daily running of the admin to 
and from Professor Marques.   
 
To everyone else in the Department of Chemistry who assisted with the project daily, thank you 
very much.
  
 
 
Publication 
 
Robinson J., Cukrowski I., Marques H.M., J.  Mol. Struct., 825, (2006), 134-142. 
 
 
 
 
 
 
 
 
 
 
  
 
 
Table of Contents Page 
 
Abstract iii 
Acknowledgements iv 
Publication v 
Table of Contents vi 
List of Figures ix 
List of Tables xi 
Abbreviations xii 
Chapter 1: Introduction 1  
1. Overview of bone cancer                            1 
Bone metastasis                         1 
 A possible mechanism for lytic tumour growth                                              
2 
2. Bisphosphonates (BP) and their use in cancer treatment         3 
 The relative activity of bisphosphonates on bone resorption        4 
3. Literature survey- previous molecular modelling of bisphosphonates         6 
4. Molecular modelling              8 
 Quantum chemistry              8 
 The Born-Oppenheimer approximation (BOA)         9 
 Molecular orbital (MO) calculations           9 
 Hartree product and Slater determinant          9 
 Molecular orbital calculations         10 
 Hartree-Fock (HF) approach        10 
 Roothaan-Hall (RH) approach        11 
Semi-empirical methods           11 
Force field calculations           12 
 
  
 
 
 
 
 
 Page 
5. Optimisation of the force field         16 
 Derivative methods          16 
 Steepest descent method        16 
 Conjugate gradient methods       17 
6. Simulated annealing.          17 
7. Aim            18 
 
Chapter 2: Experimental        19 
1. Choice of force field parameterisation        19 
1.1.   GAFF Force Field          20 
2.   Crystal structures           22 
2.1.    Preparation of crystal structures for molecular modelling    22 
 2.1.1.   Allocation of partial charges       28 
3.   Preparation of the force field         30 
4.   Modelling of the bisphosphonates (BPs)        33 
5.   Interactions with the bone surface         33 
5.1.    The hydroxyapatite surface, Ca5(PO4)6(OH)2       33 
5.2.    Interactions of the bisphosphonates with the hydroxyapatite surface    35 
 
Chapter 3: Results and Discussion       40 
1. Modelling of the bisphosphonates        40 
1.1.    Semi-empirical methods versus ab initio calculations    41 
2. The modelling of the ligands        42 
3.  Simulated annealing of the bisphosphonates      45 
  
 
 
4.  Modelling of the interactions of the bisphosphonates with hydroxyapatite  46 
      4.1.     Modelling of the hydroxyapatite surface      46 
      4.1.1.  The (001) face of hydroxyapatite      46 
      4.1.2.   The (010) face of hydroxyapatite      47 
                 4.1.3.   The (100) face of hydroxyapatite      47 
      4.2.     Testing of the effect of the relative permittivity     48 
      4.3.      Interactions of the bisphosphonates with the hydroxyapatite surface                  51 
        4.3.1. Interactions of the mono-protonated bisphosphonates with the   51 
hydroxyapatite surface 
4.3.1.1.  Interactions with the (001) face of hydroxyapatite  54 
4.3.1.2.  Interactions with the (010) face of hydroxyapatite  57 
4.3.1.3.  Interactions with the (100) face of hydroxyapatite  58 
         4.3.2. Interactions of the di-protonated bisphosphonates with the  60  
        hydroxyapatite surface 
      4.3.2.1.  Interactions with the (001) face of hydroxyapatite  61 
                              4.3.2.2.  Interactions with the (010) face of hydroxyapatite  63 
                              4.3.2.3.  Interactions with the (100) face of hydroxyapatite  64 
Chapter 5: Conclusion         66 
Chapter 6: Future Work        67 
Chapter 7: Appendix         68 
Chapter 8: References                100 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
List of Figures 
 
Figure 1:   The cycle of tumour growth. 
Figure 2:   A generalised bisphosphonate. 
Figure 3:   Examples of first (a), second (b) and third (c) generation bisphosphonates. 
Figure 4:   A comparison of Hooke’s law versus a Morse potential function. 
Figure 5:   The torsion angle is defined by the angle formed by the three red bonds. 
Figure 6:   Example of a charge distribution for a bisphosphonate. 
Figure 7:   Illustration that the linear combination of two Gaussian orbitals is a Gaussian orbital  
Figure 8:   (001), (010) and (100) faces of hydroxyapatite. 
Figure 9:   Partial charges for the smallest unit of hydroxyapatite, Ca5(PO4)6(OH)2. 
Figure 10: Atom types for the bisphosphonate backbone. 
Figure 11: Overlay of alendronate (fully deprotonated) obtained from simulated annealing and 
from force field calculations. 
Figure 12: Representation of a surface cavity and an octahedral cavity present on (001) surface of 
hydroxyapatite. 
Figure 13: Representation of the (010) surface of hydroxyapatite showing translation along the c 
axis. 
Figure 14: Representation of the (100) face of hydroxyapatite showing translation along the a 
axis. 
Figure 15: Side-on and top view of the overlaid structures of (A,B) APD and (C,D) HEDP on the 
(001) face of hydroxyapatite generated from a common starting structure in which the 
ligand was 10Å from the surface of hydroxyapatite and allowed to relax onto the 
surface, whilst changing the dielectric constant between 75ε0 and 10 ε0. 
Figure 16: Graphical representation showing the dependence of the total energy of the minimised 
structure on the relative permittivity. 
Figure 17:  Representations of the interaction of the bisphosphonates with the (001) face of 
hydroxyapatite (represented by: A-C: HEDP, D-E: alendronate). 
  
 
 
Figure 18:  Dependence of the interaction energy of five bisphosphonate ligands and the (001) 
face of hydroxyapatite on the molecular volume of the ligand. 
Figure 19:  Representations of the interactions of the two conformations A and B adopted by the 
bisphosphonates when interacting with the (010) surface of hydroxyapatite 
(represented by HEDP). 
Figure 20:  Representations of the interactions of the two conformations A (represented by 
alendronate) and B (represented by HEDP) adopted by the bisphosphonates when 
interacting with the (100) surface of hydroxyapatite. 
Figure 21:  Species distribution for APD (A), alendronate (B) and neridronate (C). 
Figure 22:  Representation of the interaction between the (001) surface of hydroxyapatite and 
neridronate, [H2L2-]. 
Figure 23:  Representation of the intramolecular hydrogen bond present in the di-protonated 
bisphosphonates when interacting with the (001) surface of hydroxyapatite 
(represented by neridronate). 
Figure 24:  Graphical representation showing that as the length of the Cα chain increases so the 
interaction energy increases. 
Figure 25:  The interactions of the two conformations A and B of di-protonated alendronate with 
the (010) surface of hydroxyapatite. 
Figure 26:  Representation of the interaction of conformation A (represented by alendronate) and 
B (represented by APD) of the di-protonated bisphosphonates with the (100) surface 
of hydroxyapatite. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 
List of Tables 
 
Table 1:   The antiresorptive potency of a series of bisphosphonates  
Table 2:   Definition of atom types 
Table 3:   Numbering system 
Table 4:   Additional parameters added to GAFF for the modelling of bisphosphonate ligands 
Table 5:   Unpublished acid dissociation constants determined by glass electrode potentiometry 
in our laboratory (298 K and µ=0.15 M NaCl) 
Table 6:    Partial charges on five bisphosphonate ligands in their monoprotonated and di- 
protonated forms as determined from a SCF-RHF calculation at the crystal structure 
geometry using a 6-31G* basis set 
Table 7:     Partial charge distribution for the bisphosphonate backbone atom types 
Table 8:    Comparison of bond lengths and bond angles obtained using structures with partial 
charge distributions obtained from PM3 and RHF methods 
Table 9:     Comparison of the bond lengths and bond angles of bisphosphonate ligands observed 
crystallographically and those predicted using molecular mechanics and GAFF 
Table 10:   Comparison of the bond lengths and bond angles of bisphosphonate ester ligands 
observed crystallographically and those predicted using molecular mechanics and 
GAFF  
Table 11:   Change in strain energy, ∆Es, for the interactions of APD and HEDP with the (001) 
surface of hydroxyapatite as a function of the relative permittivity. 
Table 12:   Change in strain energy, ∆Es, for the interactions of the mono-protonated 
bisphosphonate ligands with the three surfaces of hydroxyapatite  
Table 13:   Interaction of bisphosphonates with hydroxyapatite: distances between oxygen atoms 
of phosphonates and the nearest calcium ions on the (001) face of hydroxyapatite 
Table 14:   Interaction energies of di-protonated nitrogen containing bisphosphonates with the 
various faces of hydroxyapatite 
 
 
 
 
 
 
  
 
 
 
Table of Abbreviations 
 
Abbreviation  
AMBER assisted model building and energy refinement  
BOA Born-Oppenheimer approximation 
BP(s) bisphosphonate (s) 
CHARMM Chemistry at Harvard Macromolecular Mechanics  
CoMFA comparative molecular field analysis 
CSD Cambridge structural database  
FPP farnesyl pyrophosphate 
GAFF generalised AMBER force field  
GGPP geranylgeranyl pyrophosphate 
GPP geranyl pyrophosphate 
HF Hartree-Fock 
HP Hartree product 
IPP isopentenyl pyrophosphonate 
MM2, MM3 Allinger’s MM2 and MM3 force field  
MO molecular orbital 
NMR  nuclear magnetic resonance 
OPLS optimised potentials for liquid simulations  
PRPP phosphoribosylpyrophosphate 
PRT purine phosphoribosyltransferase 
PTHrP parathyroid hormone related protein 
RH Roothaan Hall 
RHF restricted Hartree-Fock 
SD Slater determinant 
SE Schrödinger equation 
TcHPRT trypanosoma cruzi 
TGF-β transforming growth factor β 
UFF universal molecular mechanics force field [28] 
WitsGAFF our version of GAFF 
  
 
 
XRD x-ray diffraction 
 
 
Chapter 1: Introduction 
 
1. Overview of bone cancer 
 
Cancer is a group of diseases consisting of more than one hundred different types. Cancer is 
present when cells become abnormal. These cells subsequently grow and destroy body tissue 
and are even capable of spreading to other parts of the body [1].  
 
Healthy cells that make up the body's tissues grow, divide, and replace themselves in an orderly 
way. This process keeps the body in good repair but cells that lose the ability to control their 
growth grow too rapidly and without any order. This leads to the formation of too much tissue; 
this extra tissue is called a tumour. Tumours can be benign or malignant. Benign tumours are 
non-cancerous and are seldom life-threatening whereas malignant tumours are cancerous. 
Malignant tumours invade and destroy nearby healthy tissues and organs [1]. 
 
Bone cancer can originate at the bone (primary bone cancer) or have spread to the bone from 
another organ (secondary or metastic bone cancer).   The primary sources for secondary bone 
cancer are tumours from breast, lung, prostate and renal cancer [2-4].   The focus of the work in 
this dissertation relates to secondary cancer.  
 
Symptoms of bone cancer develop slowly with the most frequent initial symptom being terrible 
pain. Other common symptoms include the presence of a firm, slightly tender lump on the bone 
that can be felt through the skin (this is due to calcemia), bone fracturing [4] and spinal cord 
compression [5].  The presence of bone metastasis is determined by radiography and bone 
scans. 
 
  
 
 
1.1. Bone metastasis 
Bone consists of both organic and cellular elements containing minerals, cytokines, growth 
factors, bone and hematopoietic cell lines. Healthy bone is always remodelling. This is 
characterised by two opposite actions, the formation of new bone by osteoblasts and the 
resorption of the old bone by osteoclasts. If this cycle is disturbed by a tumour, lesions will 
form.   A lytic lesion occurs when the resorption of the bone occurs more rapidly than the 
deposition thus leading to pits in the bone; a blastic lesion occurs when the rate of deposition is 
greater than that of resorption, which leads to the formation of a soft lump on the bone.  As this 
lump is very soft, the bone is fragile and can break easily. It is also possible for an imbalance to 
occur in both processes thus leading to the formation of a mixed lesion [2].  
 
1.1.1. A possible mechanism for lytic tumour growth  
During resorption, the bone releases cytokines and growth factors, which interact with the 
tumour.  The tumour releases cell signals that stimulate the osteoclasts.   In the formation of 
osteolytic lesions these signals include the release of the parathyroid hormone related protein 
(PTHrP) and the transforming growth factor β (TGF-β). The tumour cells produce excess TGF-β, 
thus stimulating osteoclastic bone resorption that in turn leads to the release of TGF-β by the 
bone. These elevated levels of TGF-β stimulate the metastic capability of the tumour and the 
tumour’s ability to produce PTHrP. Thus a cycle is formed that leads to tumour growth and the 
development of large lesions [2].    Figure 1 shows a graphical representation of this process. 
 
Figure 1: The cycle of tumour growth [2] 
Common treatments for bone cancer include surgery, radiation therapy, hormone treatment, 
radioisotopic treatment, and/or chemotherapy. Usually it is necessary to use a combination of 
  
 
 
treatment methods, dependent on the patient's needs.   For most bone cancer patients surgery is 
necessary.  During surgery the tumour and the healthy bone and tissue from around the tumour 
are removed [2,4]. 
Chemotherapy uses a combination of drugs which are administered orally or intravenously to 
kill cancer cells.  These drugs travel through the blood stream to the infected area where they 
kill the cells.  The treatment is given in a cycle of treatment periods followed by recovery 
periods. Chemotherapy is almost always used to shrink a tumour before surgery. In addition, it 
is usually used as an additional therapy after surgery to kill cancer cells that may remain in the 
body and to prevent tumour regrowth. For certain bone cancers, chemotherapy is combined 
with radiation therapy [2,4].  
 
Often cancer treatment involves the use of high-energy rays to damage cancer cells and to stop 
cell growth. This is known as radiation therapy.   In some cases, radiation therapy is used 
instead of surgery to destroy the tumours. This form of treatment is also used to destroy cancer 
cells that remain in the area after surgery [2,4]. 
 
Radioisotopic treatment has become a common treatment for bone cancer.  Radioisotopic 
treatment involves the use of several radiopharmaceuticals that are administered intravenously. 
These radiopharmaceuticals attack the tumour, even at very low concentration, by emitting 
radiation to kill the tumour. A commonly used series of radiopharmaceuticals are the 
bisphosphonates [2-10]. 
 
2. Bisphosphonates (BP) and their use in cancer treatment 
 
Bisphosphonates are chemically and biologically equivalent to naturally-occurring inorganic 
pyrophosphate [6,11].  They are a group of compounds that contain a P-C-P backbone structure 
with two phosphonic acid groups attached to the same central carbon atom as illustrated in 
Figure 2.  
 
 P P
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O
OH
R1
OH OH
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Figure 2:  A generalised bisphosphonate 
 
BPs were originally used in industry for fertilizers, oil and textiles but in the late 1960’s they 
began being used in medicine [3].  Their uses in medicine include treatments for bone diseases 
such as osteoporosis, hypercalcemia, Paget disease and bone metastasis [2-12] . 
 
The exact mechanism by which BPs inhibit bone resorption is not yet fully understood.  BPs 
have a high affinity for bone minerals thus preventing calcification and inhibiting the 
dissolution of hydroxyapatite crystals (principal mineral in bone, Ca10(PO4)6(OH)2) [11].   
Clinical research has shown that in breast and prostate cancer bisphosphonates can prevent the 
attachment of tumours to the bone matrix thus preventing secondary bone cancer [13]. Clinical 
data also suggest that the presence of bisphosphonate treatment decreases tumour cell growth 
and increases the efficiency of antineoplastic therapy [14].  BPs (even at very low 
concentrations) inhibit the precipitation of calcium salts [2,3,8,13], and since bone metastasis 
often leads to raised calcium levels in the blood, this is extremely useful [2].  BPs are used to 
coordinate beta-emitting radionuclides, such as samarium-153 and rhenium-186, for bone 
cancer treatment [9-11].  
 
2.1. The relative activity of bisphosphonates on bone resorption 
The activity of the BPs varies from one compound to another; thus much research needs to be 
done into the specific activity of each compound.  The relevant potency (the ability to inhibit 
resorption) is dependent on the substituents on the central carbon atom.  Three classifications of 
BPs are currently available: first generation BPs have simple substituents on the central carbon 
atom, second generation BPs have an aliphatic amine containing a chain and third generation 
BPs contain a hetrocyclic substituent (Figure 3).   
  
 
 
 
 
 
 
 
. 
 
 
 
Figure 3:  Examples of first (a), second (b) and third (c) generation bisphosphonates 
The 3rd generation BPs are the most potent [7].  Table 1 shows the relative potencies of some 
common bisphosphonates using etidronate as the reference point [11].  
 
Table 1: The antiresorptive potency of a series of bisphosphonates [11] 
Bisphosphonate R1 R2 Potency 
Clodronate Cl Cl ~ 10×  
Etidronate OH CH3 ~ 1×  
Pamidronate OH (CH2)2NH2 ~ 100×   
Alendronate OH (CH2)3NH2 >100 < 1000×  
Neridronate OH (CH2)5NH2 ~ 100×  
Olpadronate OH (CH2)2N(CH3)2 > 100 < 1000×  
Ibandronate OH (CH2)2N(CH3)(CH2)4CH3 > 1000 < 10000×  
Risedronate OH CH2-3-pyridine > 1000 < 10000×  
Zoledronate OH CH2-imidazole > 10000×  
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From Table 1 it is seen that the nitrogen-containing BPs (second generation) have a greater 
potency than the first generation BPs.  This is due to the fact that the nitrogen-containing BPs, 
in addition to inhibiting bone resorption, also inhibit osteoclastic function [2].    
 
The exact relationship between the nature of the carbon substituents and the potency is not yet 
clear.  Thus it would be useful to try to construct a predictive knowledge base. One of the 
predictive tools that could be incorporated in such a knowledge base and that we attempted to 
develop in this project was molecular modelling. 
 
3. Literature survey— previous molecular modelling of bisphosphonates  
 
Limited molecular modelling has been performed on bisphosphonate ligands.  Neves et al. [15] 
used the CVFF 950 molecular mechanics force field to study the structure of  pamidronate ( R1 
=  (CH2)2NH2), R2 = OH, Figure 1), alendronate (R1 = (CH2)3NH2, R2 = OH) and neridronate 
(R1 = (CH2)5NH2, R2 = OH) in vacuo.  They found that intramolecular hydrogen bonding 
between the terminal amino group and the hydroxyl group is the dominant interaction in 
pamidronate and alendronate, so that the amino group is gauche to the backbone carbon. For 
neridronate the intramolecular hydrogen bonding is less significant, and the trans conformation 
is favoured.  The interactions with the (001) face of hydroxyapatite were examined, as this is 
believed to be the fastest growing face [16].  It was found that the most important interactions 
occurred between the phosphonate and the amino groups of the bisphosphonate ligands and the 
calcium ions of hydroxyapatite [15].  The distance between the nitrogen atom and the nearest 
calcium ion is lowest for alendronate (3.75 Å, compared with 5.77 Å for pamidronate and 5.07 
Å for neridronate) implying that the stabilising interaction energy for alendronate is more 
significant than for the other ligands.  This is in agreement with in vivo studies, which have 
shown that the pharmacologic activity of alendronate is an order of magnitude larger than the 
other two ligands [17].  
 
In vitro studies have shown that nitrogen-containing bisphosphonates inhibit isopentenyl 
pyrophosphonate (IPP) isomerase/farnesyl pyrophosphate (FPP) in a dose-dependent manner 
which mimics the in vivo bone antiresorptive properties [18].  Similarly these ligands also 
inhibit farnesyl pyrophosphate/geranylgeranyl pyrophosphate (GGPP) synthase in plants 
[19,20].  Martin and co-workers [21] used molecular graphics methods to examine the 
  
 
 
interaction of nitrogen-containing bisphosphonates of known structure as well as a naturally-
occurring bisphosphonate equivalent, geranyl pyrophosphate, GPP (a known 
isomerase/synthase inhibitor), with FPP synthase to determine how these interact at the binding 
site.  The results showed that bisphosphonates and GPP interacted similarly with FPP synthase 
demonstrating that bisphosphonates should have an effect on the resorption of bone.  It was 
found that alendronate mimicked bound GPP the closest with a r.m.s. fit of  0.3 Å, implying 
that alendronate is the best ligand to inhibit bone resorption [21]. 
 
It is known that high levels of pyrophosphate are present in many of the major human disease-
causing parasitic protozoa [22-25] and it has been shown that bisphosphonates have inhibitory 
effects on various parasite enzymes [26].  Szabo and Oldfield [27] used molecular mechanics 
(with a universal molecular mechanics force field, UFF [28]) to carry out a qualitative analysis 
of a series of known bisphosphonate structures and of imidodiphosphonate. Comparative 
molecular field analysis (CoMFA) was used to construct a rectangular energy grid for each 
molecule.  Each molecule was compared with the most active molecule, aminomethylene 
bisphosphonate, by performing a r.m.s.-fitting of the pharmacophoric atoms of each molecule. 
They were then allowed to explore conformational space near to V/H+-PPase (proton pumping 
vacular pyrophosphatase found in the mung bean).  It was concluded that the major component 
in the interaction of a bisphosphonate with the enzyme is ionic in nature and it was suggested 
that bisphosphonates can be used as inhibitors for these parasitic diseases [27]. 
 
Trypanosoma cruzi (TcHPRT) is the causative agent in the deadly Chaga’s disease.  It is 
believed that purine phosphoribosyltransferase (PRT) is an inhibitor of these parasitic diseases 
[29,30].   Fernandez and co-workers [31] compared the interactions of both the bisphosphonates 
and HPRT, hydroxanthine-guanine PRT,  with TcHPRT.   
 
PRPP (phosphoribosylpyrophosphate) was used to represent the TcHPRT.  A Monte Carlo 
procedure was used to explore the conformational space available to a series of 
bisphosphonates.  These structures were then compared with the HPRT complex and then 
docked in the close proximity of the PRPP.  The results show that these structures would bind 
well to PRPP, suggesting a use for these ligands in drug design. 
  
 
 
4. Molecular modelling 
4.1. Quantum chemistry 
The behaviour of very small particles, such as electrons and nuclei of atoms and molecules, is not 
correctly described by classical Newtonian mechanics, because of their wave-like properties and 
the uncertainty principle.  Thus it is necessary to use an alternative method.  A series of laws 
have subsequently been defined for this application - these are the laws of quantum mechanics 
[32]. 
 
The fundamental equation of quantum mechanics is the full time-dependent Schrödinger 
equation (SE) (equation 1), 
 
( ) ( ) ( )
2 2 2 2
2 2 2
,
, 1
2
t
V t i
m x y z t
∂ ∂ ∂ ∂Ψ
− + + + Ψ =
∂ ∂ ∂ ∂
   
  
   
r
r
h
h K
 
 
which refers to a single particle of mass m moving through space r (three dimensional position 
vector) and time t under the influence of an external force V;  h  is Planck’s constant divided by 
2pi and i is the imaginary number 1− .  ( ), tΨ r  refers to the wavefunction that describes the 
motion of the particle.   
 
When the external force is independent of time the wavefunction can be divided into the 
contribution due to spatial arrangement and the contribution due to time.  Then by assuming that 
the potential is independent of time the SE can be simplified to the time-independent SE 
(equation 2). 
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Then by introducing the Hamiltonian operator (equation 3) on the left hand side of the equation 
the time-independent SE can be simplified to equation 4.  
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To solve the time-independent SE it is necessary to determine the values for the energy E and for 
the wavefunction.   These equations allow one to calculate various properties of the system such 
as potential energy and kinetic energy of the single nucleus.  The problem is that it is impossible 
fully to solve the time-independent SE for polyelectronic atoms or molecules as the mathematics 
of the system becomes too complex.  Therefore it is necessary to make various assumptions [32-
34]. 
4.1.1. The Born-Oppenheimer approximation (BOA) 
The BOA states that the motion of the electrons can be decoupled from the motion of the nuclei.  
Since the mass of the nucleus is much larger than that of the electron, the electron will be able to 
adjust to any positional change of a nucleus almost instantaneously, i.e. the nucleus will appear 
stationary when considering the motion of the electron.  Thus the wavefunction is only dependent 
on the position of the nuclei and the electronic energy of the system.  The electronic energy 
comprises the kinetic and potential energies of the electrons moving in the electronic field.  
When applying the BOA to calculations, it is assumed that the positions of the nuclei are fixed. 
 
This approximation is useful for small molecules where the number of electrons is small but is 
impractical for larger molecules as the number of electron-electron repulsions will be too large to 
calculate in a reasonable time i.e. the calculations become computationally prohibitive.  It is 
more practical to use molecular orbital methods. 
4.2. Molecular orbital (MO) calculations 
4.2.1.  Hartree product and Slater determinant 
A possible functional form of the wavefunction is the Hartree Product (HP, equation 5). 
 
 
The energy of this system is equal to the sum of the one-electron spin orbitals; this implies that 
the probability of finding one electron at a specific point is independent of finding another 
electron at that point in space.  This is not strictly correct as there is a correlation between the 
motion of the electrons.   The HP also assumes that the electrons are assigned to specific orbitals.  
This assumption disagrees with the antisymmetry principle, which states that electrons are 
indistinguishable.  For a polyelectronic system, a determinant that obeys the antisymmetry 
principle, is used to represent the functional form.  This functional form is known as the Slater 
Determinant (SD, equation 6).  The SD allows for interactions between electrons but in addition 
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it also obeys Pauli’s Principle (two electrons cannot have the same set of quantum numbers) 
since if two electrons did have the same quantum numbers the determinant would break down. 
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4.2.2. Molecular orbital calculations 
For MO calculations performed on molecules each molecular orbital is expressed as a linear 
combination of atomic orbitals (equation 7). 
 
 
 
 where iυ is the molecular orbital, µφ  is an atomic orbital and icµ  is a coefficient.   The first step 
in a molecular orbital calculation is to determine the energy of the system.  This is calculated by 
using equation 8. 
 
 
 
For a large system these integrals are very difficult and time-consuming to determine thus it is 
necessary to make some approximations.  The two common ab initio (or from first principles) 
approaches used are the Hartree-Fock approach and the Roothaan-Hall approach. 
 
4.2.2.1. Hartree-Fock (HF) approach 
For a large system, there are various functional forms of the wavefunction.  Thus it is necessary 
to determine which is the best form for the application.  This is determined by using the variation 
theorem which states that the energy calculated from an approximation to the wavefunction will 
always be greater than the actual energy of the system.  The HF equations are obtained by 
constraining the energy expression to a minimum ( 0E∂ = ) such that the orbitals are orthonormal 
to each other.  By using various mathematical methods the HF equations are simplified to 
equation 9 [33]. 
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fi is known as the Fock operator, Ji is the coulombic operator and Ki is the exchange operator.  An 
assumption used when doing a calculation is that each electron is moving in a fixed field 
consisting of nuclei and other electrons, in other words the solution for one electron will affect 
the solution for another electron.  The strategy used to solve these calculations is the Self-
Consistent Field approach.  A set of trial solutions for the molecular orbitals are used to calculate 
the coulombic operator and exchange operator; these in turn are used to calculate the HF 
equations.  From these results the new set of molecular orbitals are calculated.  This method is 
iterated until the results for the electrons are statistically equivalent. 
 
Often direct solutions for molecules are impractical and thus each spin orbital can be written as a 
linear combination of single electron orbitals.  These one electron orbitals are known as a basis 
set and often correspond to the atomic orbitals.   The size of the input basis set will be dependent 
on the computational efficiency and needed accuracy for a specific calculation.  The basis sets 
are usually used with the Slater Determinant functional form of the wavefunction. 
 
4.2.2.2. Roothaan-Hall (RH) approach 
The RH equations are based on the HF equations but to promote calculation efficiency the 
equations are adapted into a matrix form, which computationally is easier to work with.  These 
equations are used as the basis for many semi-empirical methods [35,36].     
 
  
 
 
  
 
 
4.3. Semi-empirical methods 
Ab initio calculations are extremely time-consuming and expensive on computer resources 
whereas the semi-empirical methods are much simpler to solve.  They incorporate experimentally 
determined parameters rather than determining them during the calculation.  For many 
calculations these simplifications are sufficient.  As stated above these approximation methods 
are based on the RH equations.  Many approximation methods are currently in use [32-34]. 
4.4. Force field calculations 
While quantum mechanics is extremely useful, it is often impractical for many chemistry 
problems as the number of electrons in the system is too large.  Therefore another method is 
needed.  Molecular mechanics (or force field methods) ignores the electronic motions of the 
system and calculates the energy of the system as a function of the positions of the nuclei only.   
 
A minimalistic force field is a mathematical model that consists of four terms that represent the 
intra- and intermolecular interactions of the system.   These terms are the potential energies to 
stretch a bond, to bend an angle, to distort a torsion and non-bonded interactions, including van 
der Waals and electrostatic interactions.  The bond stretching and angle bending terms are 
referred to as the hard ‘degrees of freedom’ as large amounts of energy are needed to distort the 
bonds and angles from equilibrium while the torsions and non- bonded interactions are softer in 
nature.  
 
The bond stretching term is best represented by a Morse potential (equation 10, Figure 4) but due 
to the lack of computational efficiency, it is more economical to use a Hooke’s law formula 
(equation 11, Figure 4).  The Hooke’s law formula is as accurate as the Morse potential provided 
that the deviation from the equilibrium length is not large. 
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Figure 4:  A comparison of Hooke’s law versus a Morse potential function 
 
Hooke’s law says that the energy to stretch a bond is proportional to the square of the 
displacement from the equilibrium length lo.  The equilibrium length is a reference length (or 
strain-free length), which is the length that the bond will adopt when all other terms in the force 
field are set equal to zero, and k is a force constant. These parameters are input parameters.  This 
term is the largest contributing term to the potential energy of the system.  
 
The angle bending term also uses the form of a Hooke’s law equation (equation 12), where 0θ  is 
the reference angle and k is a force constant that can be determined by a variety of methods.  Less 
energy is needed to distort an angle away from equilibrium than to stretch a bond.  Thus the force 
constants are much smaller in magnitude. 
 
 
 
A proper torsion is a rotation about a bond; thus it is the angle made between two bonds (Figure 
5).    
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Figure 5: The torsion angle is defined by the angle formed by the three red bonds. 
 
In flexible molecules the major changes in conformational arrangements are due to rotations 
about the bonds.  Thus it is necessary that a force field can model these rotations effectively.  The 
torsional term is usually represented by a cosine series expansion (equation 13) with torsional 
angleω .  The barrier height (Vn) gives a qualitative indication of the barrier to rotation present in 
a bond compared with another bond.    Some force fields such as AMBER [37-40] use a single 
term cosine function for most of the torsions while others such as MM2 [41] use a larger 
expansion.   The multiplicity (the number of minimum points in the function when the bond is 
rotated through 360o) of the torsion is represented by n and γ  is the phase factor, which 
determines where the torsion passes through the minimum value. 
 
 
 
Improper torsions or out of plane terms are also present in most force fields.  An improper torsion 
is the energy needed to keep a sp2 hybridised atom’s molecular geometry planar.  Either a cosine 
term (equation 14a) or a harmonic potential formula (equation 14b) can be used to force the 
improper torsion to be 0o or 180o.  
 
 
 
 
Equation 14a is the most common approach as this term can be incorporated into the torsion 
terms.  This equation takes into account the three atoms bonded to the sp2 hybridised atom.  
Terms that are described by equation 14b are called out-of-plane terms.  The out-of-plane energy 
is determined by a Hooke’s law equation using either the out-of-plane angle or uncorrected 
height.  The out-of-plane angle is the angle that the equilibrium bond would make with the 
horizontal plane if there was no out-of-plane torsion present and the uncorrected height is the 
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height that the third atom would be above the horizontal surface if the bond was uncorrected.  
These details are then used to determine the energy needed to counteract this equilibrium thus 
holding the torsion in the plane. 
 
The non-bonded interactions term can be divided into electrostatic interactions and van der 
Waals interactions.  The electronic structure of a molecule is often represented as an arrangement 
of point charges throughout the molecule.   The electrostatic interactions are calculated as the 
interaction between each of these point charges.  This is modelled by using a Coulomb’s law 
formula (equation 15). 
 
  
 
qi and qj are the two charges, rij is the distance between the two charges and ε0 is the permittivity 
of a vacuum.   
 
The van der Waals interactions are divided into attractive interactions and repulsive interactions.  
The dispersive interactions are predominantly caused by London forces. London forces are 
caused by an instantaneous dipole, which arises due to a fluctuation in the electron cloud. This 
dipole can thus induce another dipole.  The dispersive interaction is usually of the order of r-6 
where r is the separation distance [32].    
 
The repulsive interactions are often called exchange forces. These interactions are stronger the 
smaller the separation is. Often they are mathematically expressed as an exponential function or 
by a r-12 term [32]. 
 
The best-known function to model the van der Waals interaction is the Lennard-Jones 12-6 
function (eq. 16). 
                                            
 
 
 
where σ is the collision diameter (the separation distance at which the energy is at a minimum) 
and ε is the well depth (the energy value at the minimum). 
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5. Optimisation of the force field 
 
The potential energy of the system is a complex, multidimensional function that is dependent on 
the atomic coordinates.  As these coordinates change so the energy of the system will change 
thus leading to the formation of an energy hypersurface.  It is necessary to determine the 
minimum or minima of this surface, as these will correspond to the coordinates of the favoured 
structures.  The minima are found by applying optimisation procedures to the energy surface.   
 
The minimum of a function ( )ϕ x  is defined as the point(s) where the gradient is zero 
( ( ) 0
ix
ϕ∂
=
∂
x ) and the curvature is positive (
2
2
( ) 0
ix
ϕ∂
>
∂
x ).  Optimisation methods are divided into 
non-derivative and derivative methods.  As non-derivative methods are not useful in molecular 
mechanics only derivative methods will be discussed. 
 
5.1. Derivative methods 
Derivative methods are based on the Taylor expansion (equation 17) where O(3) represents the 
terms of order three and higher and the prime implies differentiation with respect to position.  
The order of a method is the highest order of differentiation and the methods that will be 
discussed are all first order. 
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The two most common derivative methods are steepest descent method and the conjugate 
gradient method. 
 
5.1.1. Steepest descent method 
The direction of a movement is defined by kk
k
−
=
gd
g  where gk is a vector that contains the 
partial derivatives of the function evaluated at a point xk.  The minimum can then be found using 
exact or approximate methods. 
 
An inexact line search is carried out by bracketing the minimum of the function into a region in 
space.  After each iteration the region in space is made smaller and smaller until the minimum is 
  
 
 
found.  This can be efficient if the original region is correctly captured but can be cumbersome, 
even leading to the function diverging, if the initial region was incorrectly chosen. 
 
The initial step of an exact line search is to compute a step size α  (equation 18).  Then by using 
Lagrange multipliers a solution is readily found.  The largest interatomic forces determine the 
direction of the gradient therefore relieving the highest energy features of the initial 
configuration.   
 
 
 
A problem associated with line search methods is that the method is forced to make a 
perpendicular turn at each point, which could lead to the function diverging away from the true 
minimum. 
   
5.1.2. Conjugate gradient methods 
This method does not have the same perpendicular problem as the steepest descent method thus 
error build-up is less.  In this method the gradient at each point is perpendicular but the directions 
are conjugated (equation 19).  Other methods such as Polak-Ribiere and Fletcher-Reeves are 
known to solve for kγ   
 
 
 
The problem with optimisation methods is that they only find the local minimum, so it does not 
guarantee that for a specific molecule the global energy minimum conformation is found.  A 
technique of simulated annealing is used to help find the global minimum [33]. 
 
6. Simulated annealing 
 
Since many molecules have many degrees of freedom many possible structures are possible 
dependent on the initial structure given to the force field.  In a simulated annealing calculation 
energy is added to the system in the form of extreme heat.  This is a temperature at which all 
1
(18)
k k k
α
+
= +x x d K
1
1 1
(19)
where
k k k k
k k
k
k k
γ
γ
−
− −
= − +
=
v g v
g g
g g
K


  
 
 
barriers of rotation can be overcome.   The system is then slowly cooled before minimisation.  
This allows the user to determine the most stable conformation of a specific molecule, which 
may or may not be the global minimum [33].  
 
7. Aim 
 
The aim of this project was to develop a predictive tool for the modelling of bisphosphonates 
and their interaction with hydroxyapatite, the principal mineral in bone to determine which 
bisphosphonates interact favourably with the hydroxyapatite so as to allow in vivo research into 
those interactions.  This would be one component of a knowledge base for the design of novel 
compounds to be screened as potential agents for the treatment of bone cancer. 
 
This was to be achieved by completing a series of ‘sub-aims’.  These ‘sub-aims’ included 
developing and testing a force field for the modelling of the bisphosphonates.  Once this was 
achieved it was necessary to extend and test this force field for the modelling of the 
hydroxyapatite surface.  Finally this force field was to be used to model the interactions of a 
series of these bisphosphonates with the various faces of hydroxyapatite.  These aims were to 
be achieved by using a series of tools including molecular orbital theory, molecular mechanics, 
molecular dynamics and simulated annealing.   
 
 
 
 
 
 
 
 
 
 
  
 
 
Chapter 2: Experimental 
 
1. Choice of force field parameterisation 
 
Bisphosphonates (BPs) are highly charged molecules thus it was necessary to take electrostatic 
contributions into account when using molecular modelling.  This criterion and the size of the 
BPs were used to determine which force field parameterisation to use. 
 
All molecular modelling calculations were performed using Hyperchem version 7.03 [42].  The 
force fields available in this suite of programmes are MM+ (a force field equivalent to Allinger’s 
MM2 [41] or MM3 [43]), AMBER [37,40], BIO+ (a force field equivalent to CHARM [44]) and  
OPLS [45,46].   
 
MM2 and MM3 are force fields designed predominantly for small hydrocarbons.  The charge 
distribution for a molecule is determined by summing the contribution from the van der Waals 
interactions and the electrostatic interactions.  The electrostatic interactions are calculated by 
assigning a polarisation to each bond.  This energy is calculated by using the bond dipole 
moments.  This method is sufficient for relatively non-polar molecules as the dipole moment for 
a specific bond type will be approximately the same for any molecule but for a polar molecule 
the dipole moment will vary drastically depending on the molecular structure [41,43]. As the BPs 
are highly polar this force field is inappropriate for this project.  CHARM (Chemistry at Harvard 
Macromolecular Mechanics) is a programme that uses empirical functions to model 
macromolecular systems, by separating the macromolecules into atomic units.  This force field 
models electrostatics well but since the bisphosphonates are small molecules it is not appropriate.   
OPLS (Optimised Potentials for Liquid Simulations) was developed to simulate proteins in their 
native environment, thus modelling is done to mimic an aqueous environment.  While this force 
field models electrostatic interactions well it is still inappropriate as the BP molecules do not fall 
into the set of molecules for which the force field was developed [45,46].  
 
The AMBER [37,40] (Assisted Model Building and Energy Refinement) force field was 
designed to model the simulations of nucleic acids and proteins.  The parameterisation of this 
force field takes both van der Waals and electrostatic interactions into account [37-40].  Various 
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versions of AMBER [37,40] are available for protein studies but a new force field called GAFF 
[47] (Generalised AMBER Force Field) has been developed for small molecules using the 
AMBER parametrisation [37,40].  This force field parameterisation was the one used in this 
project. 
1.1. GAFF force field  
The GAFF force field contains parameters that adequately model most organic compounds that 
contain only carbon, hydrogen, oxygen, nitrogen, sulfur, phosphorus and halogens.  The total 
strain energy, Es, is the summation of terms associated with bond stretching, angle bending, 
torsional strain, electrostatic interactions, and van der Waals interactions. 
 
Bond stretching is handled in GAFF using a simple harmonic function (equation 20) for which 
the equilibrium bond length, r0, was obtained from either the equilibrium bond lengths in the 
original AMBER [37,40] force field, from ab initio calculations using a MP2/6-31G* basis set, 
or from crystal structures. 
  
 
The bond stretching force constants where obtained by using equation 21, 
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crystallographic data and m is a power order.  The values of Kij and m were parameterised by 
means of least squares fitting to C—C, C—N and C—O bond length experimental data, and the 
original AMBER bond length parameters [40] were used. For other bond parameters, model 
molecules were constructed on which high level ab initio vibrational frequency analysis was 
performed.  The force constants were optimised using Parmscan [48].   Parmscan is an 
automatic force field parameter optimisation programme. 
 
The angle bending term in the GAFF force field is also handled by a simple harmonic function 
(equation 22) for which the equilibrium bond angle is obtained in the same manner as the 
equilibrium bond length.  
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The angle bending force constant is calculated using equation 23.  
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;   Zi and Zk are empirical values for the first and third atom in the bond and 
Cj is an empirical value for the central atom in the bond.  These were derived by using two 
hundred and fifty two bond angle parameters from the AMBER force field [37,40].   
 
GAFF treats the energy obtained from the torsional bending as a cosine function (equation 24, 
where Vi is a force constant, n is the multiplicity and φ  is the torsional angle), whereas most 
parameterisations contain one general term V1. These values were obtained by initially scanning 
a series of torsional angles at the MP4/6-31G(d,p)/MP2/6-31G* level.   These were modified by 
use of Parmscan [48] to derive the torsional angle potential to reproduce the ab initio rotational 
profile.   
 
 
 
The energy for an electrostatic interaction is obtained from Coulomb’s law (equation 25) where 
qi and qj are the charges of the atoms and rij the separation distance. 
 
 
The energy for a non-bonded interaction is calculated in GAFF [47] by a 6-12 Lennard-Jones 
potential (equation 26) 
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In this function, 
2
ir
 is half the minimum energy separation for two atoms of type i, and εi is the 
well depth for two atoms of type i [40,47].   
  
 2. Crystal structures 
 
Initially it was necessary to test the GAFF force field to determine if this force field modelled 
bisphosphonates accurately.  The structures were obtained from the Cambridge Structural 
Database (CSD) [49], which is a database of crystallographic structures for small organic 
molecules.  A search was carried out on the CSD version 5.26 (November 2004) for all 
molecules that contained a PO3-C-PO3 backbone but exclusions for molecules containing a O-P 
group or a third P group off the central carbon and coordinated metal species were excluded 
(Results in Appendix).  The search was restricted to crystal structures that met the following 
criteria:  3D coordinates are reported; not disordered; no errors; no powder structures; not 
polymeric; R-factor < 0.0075.  The reason for these criteria was so that the crystal structures 
examined are reliable.  The R-factor is a calculation of how well the charge density of a XRD 
pattern is matched to that of the structure obtained.  Therefore the lower the R-factor the better 
the fit.  The CSD results contain various structural information such as structural formula, 
compound name, density, crystallisation temperature and crystallographic data.  Each structure is 
given a randomly generated CSD reference code.  The results obtained contained sixty one 
structures (Table A1 of the Appendix) but one structure was excluded from the modelling (Table 
A2 of the Appendix).     
 
2.1. Preparation of crystal structures for molecular modelling 
These structures were obtained as textfiles, which were converted to .ent files (see Appendix), 
which are readable by Hyperchem [42].   These .ent files were then opened in Hyperchem [42], 
where solvent molecules and counter ions were erased.  These modified files were saved as .hin 
files (see Appendix), which are Hyperchem [42] specific files that contain both information for 
the spatial coordinates and the connectivity of the molecule.  
 
Once the files were converted to Hyperchem [42] compatible files all atoms were assigned atom 
types.  An atom type contains information about the nucleus including atomic number, geometry 
of the atom, spin multiplicity and atomic charge [33].  The atom types used in this project were 
obtained from the GAFF parameter files [47]   (Table 2). 
  
 
 
Table 2: Definition of atom types 
 
Atom Structural Representation Atom Type 
Carbon 
C
R1
R4
R3
R2
 
 
C3 
 
 
 
CA 
 
N
N
 
 
 
CC 
Phosphorus O
P
  
  
P5 
Oxygen 
C O
    or 
O
P
 
 
O 
 
OHR1
 
OH 
 
P
O
R1 
 
OS 
Por 
  
 
 
Hydrogen 
                  
OHR1
 
 
HO 
 
 
CH3R1
 
 
HC but if R1 is an 
electron withdrawing 
group then H1 
 
 
C
H
R1 R2
H  
R1 and R2 
electron withdrawing groups 
 
 
H2 
 
 
C
H
R1 R2
R3
 
  
R1, R2 and R3 electron withdrawing 
groups 
 
 
 
H3 
 
 
 
R1R2
H1
H3
H2 H2
 
 
H4 is a hydrogen 
next to two electron 
withdrawing 
groups.   
H5 is a hydrogen 
next to one electron 
withdrawing group. 
 
HA is an aromatic 
hydrogen 
 Any hydrogen on a nitrogen HN 
N
NH1
H2
H2  
  
 
 
Nitrogen 
N
 
 
N4 
 
N
N
 
 
NC 
 
N
 
 
NB 
 
N+
H
 
 
NA 
 N
 
 
N 
 N
O-
O-
 
NO 
 
Chlorine 
 
Any chlorine 
 
Cl 
 
  
In addition, it was necessary to number the atoms in the structures in a consistent manner as the 
code (example in Appendix) we wrote to obtain statistical information about the structures 
references specific atom numbers.  Since the structures obtained from the CSD contains both 
acids and ester derivatives of varying degrees of protonation, the structures were divided into 
eight categories dependent on functionality and degree of protonation.  The number system 
adopted is given in Table 3. 
 
  
 
 
 
Table 3: Numbering system 
 
Group Numbering 
Acids 
No protons present 
CP P
O-
O
-O
O-
O
O-
R2
R1
 
 
1 proton present 
CP P
O-
O
-O
O-
O
O
R2
R1
H
 
2 protons present 
CP P
O-
O
O
O-
O
O
R2
R1
HH
 
3 protons present 
CP P
O
O
O
O-
O
O
R2
R1
HH
H  
7 
6 
5 4 
3 2 1 
8 
9 
10 
11 
 
6 
9 
5 4 
3 2 1 
7 
8 
11 
12 
10 
 
6 
9 
5 4 
3 2 1 
7 
8 
12 
13 
11 10 
 
  8 
7 
5  4 
3  2  1 
  6 
9 
13 
14 
 10 12 
11 
  
 
 
Group Numbering 
4 protons present 
CP P
O
O
O
O
O
O
R2
R1
HH
HH  
Ester Derivatives 
1 R- group present 
CP P
O-
O
-O
O-
O
O
R2
R1
R3
 
2 R-groups present 
CP P
O-
O
O
O-
O
O
R2
R1
R3R4
 
4 R-groups present 
CP P
O
O
O
O
O
O
R2
R1
R3R4
R5R6
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  8 
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14 
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 10 13 
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6 
9 
5 4 
3 2 1 
7 
8 
12 
13 
11 10 
 
6 
9 
5 4 
3 2 1 
7 
8 
11 
12 
10 
  
 
 
2.1.1. Allocation of partial charges 
The AMBER force field [37,40] parameterisation has an electrostatic interaction term thus partial 
charges for the atoms were determined.  Restricted Hartree-Fock (RHF) ab initio calculations 
using Hyperchem [42], with a 6-31G* basis set and convergence limit 1× 10-5 kcal mol-1 with 
accelerated convergence, were performed to determine these partial charges (Figure 6).   
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Figure 6:  Example of a charge distribution for a bisphosphonate 
 
The most common basis sets are the Slater functions and the Gaussian basis sets.  The Slater 
orbitals consist of integrals that are computationally demanding, it is more efficient to use the 
Gaussian basis sets.  These basis sets have the form: 
 
where (x,y,z) are the spatial coordinates raised to integral powers a,b and c and α is the radial 
extent of the Gaussian function.  The radial spread is inversely proportional to α.  A major 
advantage of Gaussian basis sets is that the product of two Gaussians is also a Gaussian, which is 
located along the centre of the two original Gaussians.  A single Gaussian function is insufficient 
to model a system, as a Gaussian function does not have a cusp at the origin and it decays 
towards zero quicker than the Slater orbital.  This problem is easily overcome by using a linear 
combination of Gaussian functions (Figure 7) but these calculations are cumbersome.   
 
2e x p ( )a b cx y z rα−
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7:  Illustration that the linear combination of two Gaussian orbitals is a Gaussian orbital 
[33]. 
 
The size of the basis set that is used is dependent on computer efficiency and accuracy needed.  
The smallest basis sets available are the minimal basis sets that contain just the number of 
functions that are required to fill all the orbitals in the shell.  The minimal basis sets are known to 
have deficiencies for compounds containing atoms that are near the end of a period such as 
oxygen or the halogens [33]; thus a minimal basis set was insufficient for this project as the BPs 
are rich in oxygen.  These problems can be addressed if more than one function is used to 
represent each orbital. Basis sets with these functions are called double zeta basis sets but again 
these calculations are computationally cumbersome.  An alternative is to use the split valence 
approach.  These basis sets separate the valence electrons from the inner core electrons.  The 
rationale to this approach is that the inner electrons have a minimal effect on the chemical 
properties of a compound, as these properties are largely a consequence of the valence electron 
configuration the inner core electrons can be represented by one function each while the valence 
electrons require more than one function.  These functions can also take into account polarisation 
and this is denoted by a single asterisk for polarisation of all the non-hydrogen atoms and a 
double asterisk for the polarisation of all the atoms.  The basis set used in this project was the 
split valence with polarisation of the heavy atoms, 6-31G* [33].  
 
In addition partial charges were also determined by semi-empirical methods, as certain BPs were 
too large for ab initio methods.  Semi- empirical methods are divided into two main categories, 
either single Hückel method or Pariser-Parr-Pople method.  The Hückel method is a one-electron 
theory whereas Pariser-Parr-Pople is a two-electron theory.  An assumption that all semi-
 
 
  
 
 
empirical methods make is in the treatment of pi electrons in non-planar molecules, where the 
valences electrons are considered together rather than separately.   Various semi-empirical 
methods are available in the Hyperchem suite [42] but it was decided to use the PM3 method 
[50].  PM3 [50] is a two-electron theory that has parameters for twenty four elements including 
all the elements present in the bisphosphonates.  In addition PM3 [50] models the geometry and 
dipole moments of a wide range of molecules reasonably accurately [32].   
3.  Preparation of the force field 
 
A problem associated with the AMBER [37,40] force field in Hyperchem [42] is that it is 
impossible to determine if all needed parameters are present in the force field parameter files.  
The coding instructs the software to use “dummy” parameters for unknown parameters thus 
leading to errors in the modelling of structures.  This problem was overcome by setting up a test 
set of parameter files and monitoring for missing parameters using the MM+ force field 
[41,42,51] which reports missing parameters.  The test parameters were obtained by running a 
log file on each structure while running a minimisation code on the structure using the MM+ 
Force Field [41,42,51].  The log file (example in the Appendix) lists all the missing parameters 
from the test files.   
 
These parameters were added to the test parameter files (in MM+ format [41,42,51]) and to 
WitsGAFF (our version of GAFF parameter files, from the GAFF parameter files [47]).  Once all 
the structures were tested it was found that additional parameters needed to be added to the 
parameter files (Table 3).  Additional bond stretching parameters were obtained from the 
AMBER99 [39] parameters.  These parameters where optimised for our system by performing 
force field calculations (1000 iterations of steepest descent algorithm) on known crystal 
structures.  The minimised bond lengths were compared with the original crystal structures bond 
lengths.  According to the difference seen between the two structures the parameters were 
modified.  This method was repeated until the reproducibility of the bond lengths was good.  The 
angle parameters were obtained either from the AMBER99 [39] parameter files or by using the 
method determined by the developers of GAFF [47].  The additional torsions, improper torsions 
and non-bonded interactions were obtained either from AMBER99 [39] or by using the 
parameters for a similar atom type in GAFF [47].  The complete parameter files are saved on the 
disk attached to the Appendix. 
 
  
 
 
Table 4: Additional parameters added to GAFF for the modelling of bisphosphonate  ligandsa 
 
Additional angle bending parameters 
 Parameter θo /degrees kθ /kcal mol-1 deg-2 Comments 
H2-C3-P5 53.8 109.64 AMBER99 [39] 
OH-C3-P5 84.2 105.3 θo from crystal structures  
θ
k  calculated from equation 23 
H5-CA-NA 51.9 114.95 AMBER99 [39] 
C3-CA-NA 66.4 109.16 θo from crystal structures  
θ
k  calculated from equation 23 
H3-C3-P5 53.8 109.64 AMBER99 [39] 
H3-C3-N 50.0 108.93 AMBER99 [39] 
H1-C3-N4 49.0 107.90 AMBER99 [39] 
H3-C3-N4 49.0 107.90 AMBER99 [39] 
NA-CA-NH 71.4 120.98 AMBER99 [39] 
NH-C3-P5 82.4 107.70 θo from crystal structures  
θ
k  calculated from equation 23 
Cl-C3-P5 80.2 110.00 θo from crystal structures  
θ
k  calculated from equation 23 
N-C3-P5 81.3 110.50 θo from crystal structures  
θ
k  calculated from equation 23 
N4-C3-P5 80.8 114.00 θo from crystal structures  
θ
k  calculated from equation 23 
CA-C3-P5 78.9 109.70 θo from crystal structures  
θ
k  calculated from equation 23 
OH-P5-OH 43.7 106.40 θo from crystal structures  
θ
k  calculated from equation 23 
  
 
 
Parameter θo /degrees kθ /kcal.mol-1 deg-2 Comments 
CA-OS-P5 87.9 97.00 θo from crystal structures  
θ
k  calculated from equation 23 
P5-C3-Br 82.4 108.50 θo from crystal structures  
θ
k  calculated from equation 23 
C-CA-NA 67.5 118.00 θo from crystal structures  
θ
k  calculated from equation 23 
O-CA-NA 74.9 119.70 θo from crystal structures  
θ
k  calculated from equation 23 
C3-OS-NA 64.5 110.40 θo from crystal structures  
θ
k  calculated from equation 23 
 
Additional improper torsion parameters 
Parameter Vi/2 /kcal mol-1 γ 
/deg 
n Comments 
**−**−CA−** 1.10 180 2 Preliminary value, similar to improper 
torsion parameters in GAFF[47] 
**−**−NA−** 1.10 180 2 Preliminary value, similar to improper 
torsion parameters in GAFF[47] 
 
Additional non-bonded parameters 
parameter R* /Å ε /kcal mol-1 Comments 
C0 1.7131 0.459789 AMBER99[39] 
 
Additional torsion parameters 
Parameter Periodicity Vi/2     / 
kcal mol-1 
γ /deg N 
**−C2−N3−** 4 1.20 180.00 2.00 
  
aThe symbol ** is a wildcard symbol and refers to any atom 
 
  
 
 
4.  Modelling of the bisphosphonates (BPs) 
 
Energy minimisation was performed using one thousand iterations of a steepest descent 
algorithm followed by one thousand iterations of a Polak-Ribiere conjugate gradient algorithm, 
or until reaching the converge criteria of 0.01 kcal Å-1mol-1 on crystallographic structures.      
 
The minimised structures were compared with the crystal structures.  Fits were deemed 
acceptable if bond lengths were reproduced to within 0.01 Å, bond angles to within 2o, and 
torsions to within 4o [52].  A problem was faced in determining the accuracy of the torsional 
parameters as there was free rotation about all the central bonds in the BPs.  Subsequently 
various conformational isomers where obtained for each structure.  The minimised torsional 
angles were checked by plotting the torsional distribution of each angle (see Figures A1 –A4 of 
the Appendix).  It was seen that the torsional angles all occurred at angles of approximately 60no 
where n= 0,1,2,3.  This was as predicted as at these angles the through-space interactions of the 
substituents are minimised.   
 
In addition it was necessary to determine if these minima were the global or only the local 
minimum.  This was explored by performing a simulated annealing on alendronate (R1= OH, R2 
= C3H6NH3).  The investigation was performed independently on five different alendronate 
structures.  The difference in these structures was in the number of protons present on the 
phosphonate groups ranging from no protons (fully deprotonated) to four protons present (fully- 
protonated).  The system was heated from 0 K to 500 K over a period of 5 ps.  It was held at 500 
K for 50 ps and subsequently allowed to cool (over a period of 10 ps) to 0 K.  This allowed the 
structure to overcome any barriers to rotation and to anneal into what is hopefully the global 
energy minimum structure.  These structures were compared with the minimum structures 
obtained from the force field calculation.     
5.  Interactions with the bone surface 
 
5.1. The hydroxyapatite surface, Ca5(PO4)6(OH)2 
The crystal structure reported by Kay and co-workers [53] was used for the modelling of 
hydroxyapatite.  The cell information was obtained from the Inorganic Crystallographic 
Structural Database [54] and then solved by direct methods using SHELXS-97 [55] and WINGX 
[56].  Non-hydrogen atoms were first refined isotropically followed by anisotropic refinement by 
  
 
 
full matrix least-squares calculation based on F2 using SHELXS-97 [55].  Hydrogen atoms were 
positioned geometrically and allowed to ride on their respective parent atoms.  The crystal 
structure was grown in Mercury 1.4 [57] to obtain  1×3×3, 3×1×3 and 3×3×1 crystals to represent 
the (100), (010) and (001) faces of  hydroxyapatite (Figure 8). These were then converted into a 
Hyperchem-compatible format, and atom types were assigned. The atom type C0 was added to 
the force field parameter files to represent calcium; the calcium parameters were obtained from 
the parameter files of AMBER99 [39].  A single point restricted Hartree-Fock (RHF) ab initio 
calculation using Hyperchem [42] with a 6-31G* basis set was performed on the unit cell of 
hydroxyapatite (Figure 9) and the average partial charge for each atom type was allocated to the 
entire matrix. 
 
 
Figure 8: (001), (010) and (100) faces of hydroxyapatite 
  
 
 
 
 
Figure 9:  Partial charges for smallest unit of hydroxyapatite, Ca5(PO4)6(OH)2 
5.2.  Interactions of the bisphosphonates with the hydroxyapatite surface 
An investigation of the interactions was performed for five BPs namely, MDP (R1 = R2 = H, 
Figure 1), HEDP (R1 = OH, R2 = CH3), APD (R1 = OH, R2 = (CH2)2NH3+), alendronate (R1 = 
OH, R2 = (CH2)3NH3+) and neridronate (R1 = OH, R2 = (CH2)5NH3+) with the hydroxyapatite 
surface.  The appropriate protonation of each ligand at serum pH levels (7.2) was used, utilising 
the known pKa values [58] or values that have been determined in our laboratory (Table 5).  The 
charge distributions for the chosen ligands are given in Table 6. 
 
Table 5: Unpublished acid dissociation constants determined by glass electrode potentiometry in 
our laboratory (298 K and µ=0.15 M NaCl) 
 
  pK1 pK2 pK3 pK4 
APD 1.85(1) 5.760(3) 9.62(1) 12.050(3) 
alendronate 2.07(1) 6.10(1) 10.498(5) 11.41(1) 
neridronate 2.36(1) 6.43(1) 10.86(1) 11.21(1) 
 
Oxygen on phosphate 
groups - 0.953 
Calcium 
1.363 
Phosphorus 
1.757 
Oxygen on hydroxyl group-
1.075 
 Hydrogen on 
hydroxyl group 0.425 
  
 
 
Table 6: Partial charges on five bisphosphonate ligands in their mono-protonated and di-
protonated forms as determined from a SCF-RHF calculation at the crystal structure 
geometry using a 6-31G* basis set 
 
Structure 
 
                                    Charge Distribution/ electron units 
Mono-protonated species 
MDP 
P P
O O
OHO
O O
H
H
-0.967
-1.005
-0.927
1.303
-0.907
-0.874
-0.758
0.381
-0.798
0.152
0.107
1.293
 
 
 HEDP 
P P
O O
OHO
O O
OH
H H
H
0.1400.119
0.090 -0.482
-0.895
-0.915
-1.063
1.335
-0.135
-0.878
-0.848
-0.911
0.4601.384
-0.834
0.432
 
 
 
APD 
 
 
 
 
 
 
 
 
 
 
P P
O O
OHO
O O
OH
N
H
H
H
H
H
H
H
-0.868
-0.865
0.416
-0.817
1.446
-0.201
-0.759
0.375
-0.971
-0.908
-0.906
-0.401
0.162
0.237
1.368
-0.277
0.259
0.230
-0.777
0.406
0.423
0.429
  
 
 
Structure 
 
                                    Charge Distribution/ electron units 
Alendronate 
P P
O O
OHO
O O
OH
H
H
H
N
H
H
H
H
H
0.409
0.427
0.439
-0.768
0.220
0.238
-0.284
0.180
0.143
0.213
-0.369
-0.191
H
0.232
-0.329
-0.847
-0.960
-0.686
0.396
-0.964
-0.913
-0.958
1.380
1.362
-0.725
0.355
 
 
Neridronate 
 
P P
O O
OHO
O O
OH
H
H
HH
H
N
H
H
H
H
H
H
H
-0.963
-1.006
-0.901
1.379
-0.219
-0.785
0.388
1.432
-0.918
0.413
-0.873
-0.761
-0.337
0.145
0.216
H
-0.308
0.208
0.133
-0.364
0.201
0.126
-0.352
0.125
0.232
-0.205
0.214
0.263-0.745
0.435
0.412
0.416
 
 Di-protonated Species 
 
APD 
P P
O O
OHHO
O O
OH
N
H
H
H
H
H
H
H
-0.742
0.466
-0.812
1.470
-0.971
-0.729
0.398
-0.200
-0.889
-0.852
-0.7730.496
1.413
-0.435
0.195
0.209
-0.258
0.284
0.239
-0.773
0.430
0.426
0.430
 
  
 
 
Structure 
 
                                    Charge Distribution/ electron units 
 
Alendronate 
P P
O O
OHOH
O O
OH
H
H
H
N
H
H
H
H
H
H
0.342
-0.654
-0.824
-0.887
1.376
-0.716
0.372
1.368
-0.712
0.416
-0.921
-0.817
-0.211
0.185
0.230
-0.372
-0.344
0.230
0.193
-0.274
0.237
0.248
-0.7660.423
0.433
0.411
 
Neridronate 
P P
O O
OHOH
O O
OH
H
H
HH
H
N
H
H
H
H
H
H
H
H
-0.810
0.441
-0.811
1.413
-0.888
-0.244
-0.751
0.395
-0.884
-0.850
-0.762
0.428 1.462
-0.358
0.075
0.250
-0.302
0.234
0.146
-0.367
0.122
0.213
-0.355
0.152
0.241
-0.210
0.258
0.235
-0.746
0.424
0.422
0.407
 
 
 
The interaction energies were calculated by initially minimising the energy of a bisphosphonate 
far (ca. 20 Å) from the hydroxyapatite surface (Polak-Ribiere conjugate gradient, convergence 
criterion of 0.01 kcal Å-1 mol-1) whilst all atoms of hydroxyapatite were fixed in the position 
found in the crystal structure.  The ligand was then brought closer to the surface (ca. 8 Å); energy 
minimisation (using the same method and convergence criterion) caused the ligand to relax onto 
the hydroxyapatite surface.  The difference in strain energies between the two systems is the 
interaction energy.  This was repeated twenty times, each with a different, random orientation of 
the ligand relative the hydroxyapatite surface.  The reported interaction energy is the mean of the 
twenty individual minimisations. As we wished to mimic an aqueous environment a relative 
permittivity of 78ε0 was used.  A series of tests for various relative permittivity was performed on 
HEDP and APD to determine the effect of the relative permittivity on the energy minimisation.  
  
 
 
The reason that these structures were chosen is that HEDP is a first generation bisphosphonate 
and APD is a second generation bisphosphonate, which has the amine chain present.  Using these 
two structures it was possible to determine the contribution of the relative permittivity to the 
bisphosphonate backbone and to the amine chain separately. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Chapter 3: Results and Discussion 
 
1. Modelling of bisphosphonates 
 
The atom types for the bisphosphonate backbone are given in Figure 10.    
 
Figure 10:  Atom types for the bisphosphonate backbone 
 
The partial charges for each of the structures were determined and the mean charges for the atom 
types are in Table 7.  As the standard deviation for most of the atom types (other than C3 and 
OS) is small (less than 0.1) it is sufficient to use these averages for future calculations.  The large 
standard deviation in the C3 charge is due to the large variation present in the nature of the R2 
and R3 substituents of the central carbon.   Some of the bisphosphonate structures have strong 
electron-withdrawing substituents whereas others have electron-donating substituents- therefore 
the charge on C3 will fluctuate accordingly.  The large standard deviation for OS is due to the 
size of the sample set, which contains only thirty two entries.  The charge distributions for the P5, 
C3, O, OH and HO atom types are in the Appendix Figures A5-A9.   
 
Table 7: Partial charge distribution for bisphosphonate backbone atom types 
 
Atom Type Sample Size  Average Charge /electron units 
P5 102 1.47 ± 0.08 
C3 61 -0.35 ± 0.21 
O 167 -0.82 ± 0.08 
 
O 
OH 
C3 
HO 
P5 
OS 
  
 
 
OH 138 -0.75 ± 0.09 
OS 32 -0.82 ± 0.17 
HO 138 0.44 ± 0.09 
1.1. Semi-empirical methods versus ab initio calculations 
Originally only ab initio calculations (RHF method) were used to calculate the charge 
distributions for the bisphosphonates. Unfortunately four of the ester derivative bisphosphonates 
(IGUMAY [59], JOTVET [60], MUSLUH [61], PAWTUC [62]) were too large to be studied and 
it was therefore necessary to use semi-empirical methods.  A test was performed on the other five 
ester derivatives (CAKKEF [63], IGUMEC [59], ZARJAD [64], ZARJEH [64], ZARJIL [64]) to 
determine if the semi-empirically calculated charges were sufficient.  The charge distributions for 
these structures were determined using both a RHF ab initio method and by a PM3 semi-
empirical method.  The structures were minimised by the force field and the results for the bond 
lengths and bond angles compared.   All the bond lengths obtained using the semi-empirical 
method to calculate the charges, other than the C3-C3 (central carbon on backbone- R1 = sp3 
carbon) bond, were within 0.0003Ǻ of the ab initio calculated bond lengths.  As these differences 
are less than the standard deviation for the ab initio calculated bond lengths the two methods can 
be seen as statistically equivalent. The difference between the minimised lengths for the C3-C3 
bond using the two methods was 0.0013Ǻ.  All the semi-empirical modelled bond angles were 
within 0.3o of the ab initio bond angles.  This difference was acceptable as they are all within one 
standard deviation of the ab initio structures (Table 7).   It was decided to use the PM3 semi-
empirical method to calculate the charge distributions for the large BP esters. 
 
Table 8: Comparison of bond lengths and bond angles obtained using structures with partial 
charge distributions obtained from PM3 and RHF methods 
 
Parameter PM3 RHF  Difference 
Bond Lengths/ Å 
P5-C3 1.823 ±0.003 1.823 ±0.003 0.000 
P5-O 1.495 ±0.022 1.495 ±0.022  0.000 
P5-OS 1.611 ±0.003 1.611 ±0.003  0.000 
OS-C3 1.558 ±0.200  1.558 ±0.200  0.000 
OS-CA 1.624 ±0.590  1.624 ±0.589  0.000 
C3-Cl 1.789 ±0.001  1.789 ±0.000  0.000 
  
 
 
C3-H2 1.100a  1.100 a 0.000 
C3-OH 1.432 ±0.001  1.432 ±0.001  0.000 
C3-C3 1.545 ±0.005  1.544 ±0.004  0.001 
Parameter PM3 RHF  Difference 
Bond Angles/ degrees 
P5-C3-P5 115.1±0.7 115.0±0.7 0.1 
O-P5-O 111.2±0.4 111.5±0.7 0.3 
O-P5-OS 115.1±1.4 115.0±1.5 0.1 
OS-P5-OS 104.8±3.6 104.8±3.5 0.0 
O-P5-C3 112.1±65.4b 112.1±65.4 0.0 
OS-P5-C3 104.0±5.4 103.9±5.2 0.1 
P5-OS-C3 119.4±2.1 119.4±2.0 0.0 
P5-OS-CA 89.1±36.6 89.1±36.6 0.0 
P5-C3-Cl 108.4±0.1 108.4±0.1 0.0 
P5-C3-H2 83.3±16.2 83.3±16.2 0.0 
P5-C3-OH 104.5±0.7 104.6±0.7 0.1 
P5-C3-C3 112.1±0.6 112.0±0.9 0.1 
 
 
a
 Single observation available 
b
 The large standard average is due to the arms of the substituents aligning differently in 
space 
 
2. The modelling of the ligands 
 
GAFF reproduced the structures of the bisphosphonate ligands reasonably well (Table 9 and 
Table 10).  Bond lengths were reproduced on average to within 0.015 Å of the crystallographic 
mean value, or within 1.2 mean standard deviations of the experimental observations, whilst 
bond angles were on average reproduced to within 1.9o (0.8σ).  Significant differences in bond 
lengths occur with P−O- bonds which, in the solid state structures (average 1.512 ± 0.014 Å) are 
somewhat longer than in the molecular mechanics model (1.481 ± 0.001 Å) and P−OH bonds 
(1.570 ± 0.030 Å observed; 1.628 ± 0.001 Å calculated) are somewhat shorter. There is a distinct 
possibility that ambiguity in the state of protonation of a phosphonate oxygen in the solid state 
structures has led to experimental error when the structures are solved. Bonds between the sp3 C 
  
 
 
of the bisphosphonate and an aromatic carbon (1.516 ± 0.034 Å observed; 1.539 ± 0.001 Å 
calculated) are also somewhat longer in the modelled structures than observed in the solid state.   
 
Because of free rotation about the P−C bonds, it is difficult to compare directly the torsional 
angles.  The torsional distributions for the backbone torsions (this excludes torsion involving H 
atoms as H atoms are generally not observable in structures obtained by x-ray diffraction 
methods) are seen in the Appendix Figure A1-A4.  In virtually all structures, groups adopt either 
a gauche or anti conformation (which is reproduced in the modelling) but in several cases gauche 
conformations observed in the solid state energy-minimised into anti conformations, and vice 
versa.    
 
Table 9: Comparison of the bond lengths and bond angles of bisphosphonate ligands observed 
crystallographically and those predicted using molecular mechanics and GAFF 
 
Parameter 
Solid state 
Average 
(obs) 
Standard 
Deviation 
Modelled 
Average 
(calc) 
|obs-calc| nσ a 
Bond lengths /Å 
P5-C3 1.841 0.010 1.830 0.011 1.10 
P5-O 1.512 0.014 1.481 0.031 2.21 
P5-OH 1.570 0.030 1.628 0.058 1.93 
C3-Cl 1.791 0.008 1.791 0.000 0.00 
C3-OH 1.446 0.005 1.437 0.009 1.80 
C3-C3 1.535 0.008 1.551 0.016 2.00 
C3-NH 1.468 0.010 1.467 0.001 0.10 
C3-N4 1.516 0.001 1.515 0.001 1.00 
C3-Nb 1.478  1.483 0.005  
C3-CA 1.516 0.034 1.539 0.023 0.68 
      
Bond Angles /degrees 
P5-C3-P5 113.7 2.5 115 1.3 0.52 
O-P5-O 114.5 1.9 111.2 3.3 1.74 
O-P5-OH 110.6 2.7 112.1 1.5 0.56 
  
 
 
OH-P5-OH 106.4 0.7 105.5 0.9 1.29 
O-P5-C3 108.5 1.6 110.2 1.7 1.06 
Parameter 
Solid state 
Average 
(obs) 
Standard 
Deviation 
Modelled 
Average 
(calc) 
|obs-calc| nσ a 
OH-P5-C3 105 1.1 103.8 1.2 1.09 
P5-C3-Cl 108.4 1.2 108.5 0.1 0.08 
P5-C3-OH 105.3 3.1 104.8 0.5 0.16 
P5-C3-C3 104.6 8.1 105.9 1.3 0.16 
P5-C3-NH 107.7 1.1 107.6 0.1 0.09 
P5-C3-N4 110.6 0.1 110.8 0.2 2.00 
P5-C3-N 110.5 1.2 109.5 1.0 0.83 
P5-C3-CA 109.7 1.2 109 0.7 0.58 
 
aThe difference between the mean observed and mean calculated parameter expressed as the 
number (n) of standard deviations (σ) of the experimental observations. 
bSingle observation available 
 
Table 10: Comparison of the bond lengths and bond angles of bisphosphonate ester ligands 
observed crystallographically and those predicted using molecular mechanics and 
GAFF 
 
Parameter Solid state 
Average 
(obs) 
Standard 
Deviation 
Modelled 
Average 
(calc) 
|obs-calc| nσ a 
Bond lengths /Å 
P5-C3 1.852 0.019 1.823 0.029 1.53 
P5-O 1.486 0.021 1.495 0.009 0.43 
P5-OS 1.584 0.009 1.611 0.027 3.00 
OS-C3 1.526 0.243 1.558 0.032 0.13 
C3-Cl 1.794 0.003 1.789 0.005 1.67 
C3-OH 1.428 0.005 1.432 0.004 0.80 
  
 
 
C3-C3 1.544 0.010 1.544 0.000 0.00 
Parameter Solid state 
Average 
(obs) 
Standard 
Deviation 
Modelled 
Average 
(calc) 
|obs-calc| nσ a 
Bond Angles /degrees 
P5-C3-P5 114.5 0.7 115.0 0.5 0.71 
O-P5-O 117.1 3.5 111.5 5.6 1.60 
O-P5-OS 110.9 4.2 115.0 4.1 0.98 
OS-P5-OS 103.3 1.0 104.8 1.5 1.50 
O-P5-C3 110.2 64.1 112.1 1.9 0.03 
OS-P5-C3 107.5 4.7 103.9 3.6 0.77 
P5-OS-C3 124.3 2.1 119.4 4.9 2.33 
P5-OS-CA 97.0 38.1 89.1 7.9 0.21 
P5-C3-Cl 108.5 0.2 108.4 0.1 0.50 
P5-C3-OH 104.6 1.7 104.6 0.0 0.00 
P5-C3-C3 110.1 2.5 112.0 1.9 0.76 
 
a The difference between the mean observed and mean calculated parameter expressed as the 
number (n) of standard deviations (σ) of the experimental observations. 
 
3. Simulated annealing of the bisphosphonates 
 
Minimal differences were observed for the minimised structures obtained from only force field 
calculations and for the structures obtained from simulated annealing.  The bond lengths obtained 
for the various structures (other than the P-O bonds) were approximately equivalent with a 
maximum relative standard deviation 0.1%.  The slightly larger variation in bond length for the 
P-O bond was due to the ambiguity present in the protonation of the bond (i.e. single or double 
bond present). Similarly the error in the bond angles was low other than the oxygen-containing 
angles.  These large errors are due to the change in intermolecular interactions due to the 
presence of the additional charged protons (Table A3 in the Appendix).   
  
In summary, the global minimised structures compared well with the force field calculated 
structures with all the bonds and angles being reproduced well (Figure 11).  The variations were 
  
 
 
only present in the torsions but this is due to the free rotation present in the bonds.  Therefore an 
assumption was made that the structures obtained from the force field calculations are actually 
the lowest energy structures. 
 
 
4. Modelling the interactions of the bisphosphonates with hydroxyapatite 
 
4.1.  Modelling of the hydroxyapatite surface  
4.1.1. The (001) face of hydroxyapatite 
The hydroxyapatite structure used has empirical formula Ca10(PO4)6(OH)2.  The (001) face 
contains surface Ca2+ ions in a trigonal arrangement with Ca2+−Ca2+ distances of either 9.4 or 
10.0 Å.  Immediately below this surface layer are octahedral sites defined by six Ca2+ ions, with 
OH− ions occupying opposite faces of the octahedron.  A phosphate is located approximately 
along the perpendicular bisector of each Ca2+−Ca2+ vector, 3.08 and 3.28 Å, respectively, from 
the two Ca2+ ions.  The base of each surface trigonal cavity is lined either by Ca2+ ions and an 
OH− ion of an octahedral site, or by phosphate ions (Figure 12). 
 
 
 
 
 
 
Figure 11: Overlay of alendronate (fully de-protonated) obtained from simulated annealing and from  
force field calculations 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12:  Representation of surface cavity and octahedral cavity present on (001) surface of 
hydroxyapatite 
 
4.1.2. The (010) face of hydroxyapatite 
The basic building block of the (010) surface consists of one phosphate group, one calcium ion 
and two hydroxyl groups.  This building block is translated along the c-axis, forming a row of 
alternating phosphate and calcium ions, which is parallel to a row of hydroxyl groups. These 
rows are then translated along the a-axis to form the surface (Figure 13). 
 
 
Figure 13:  Representation of the (010) surface of hydroxyapatite showing translation along the c 
axis 
 
4.1.3. The (100) face of hydroxyapatite 
 
c 
a 
  
 
 
The (100) face contains the same building block as the (010) face. This is translated along the b-
axis to form a row of alternating phosphate and calcium ions parallel to a row of hydroxyl 
groups; these rows are in turn translated along the a-axis to form the plane (Figure 14). 
 
 
Figure 14:  Representation of the (100) face of hydroxyapatite showing translation along the a 
axis 
 
4.2. Testing the effect of the relative permittivity  
The problem with using molecular modelling to investigate the interactions of BPs with bone is 
that molecular modelling calculations are performed in a vacuum.  As this does not mimic the 
“real world” environment it was necessary to compensate for this variation.  The only way to 
mimic this environment was to include a relative permittivity into our calculations to dampen the 
electrostatic interactions.  The use of 78ε0 [32,34] has been recommended  for the relative 
permittivity for an aqueous environment and as blood serum is made up of seventy percent water 
this constant seemed the most applicable.  The applicability of this constant was investigated by 
varying ε between 10ε0 and 75ε0 when modelling the interaction of APD and HEDP with 
hydroxyapatite (Table 11).  The results showed that as soon as any dampening effect was added 
to the relative permittivity, the minimised overall energy of the system dropped 10 fold in 
magnitude (Figure 16).   In addition the total and electrostatic energies obtained for any relative 
permittivity larger than 10ε0 are statistically equivalent (by < 1 kcal mol-1) but more importantly 
the structures obtained are the same for all relative permittivities (Figure 15).  As all the 
dampening effect for all constants larger than 10ε0 were equivalent the relative permittivity of 
water was used.  
 
a 
c 
  
 
 
 
 
 
Table 10: Change in strain energy, ∆Es, for the interactions of APD and HEDP with 
    the (001) surface of hydroxyapatite as a function of the relative permittivity 
 
Ligand ε /ε0 Components of the strain energy 
/kcal mol-1 
∆Es 
/kcal mol-1 
 
 
Bond 
stretching 
Angle 
bending 
Torsion Non-
bonded 
Electro-
statics 
 
APD 10 -0.02 0.07 0.05 -16.25 -13.70 -29.85 
 15 0.42 1.14 0.46 -18.79 -3.06 -19.82 
 20 0.05 0.25 0.00 -17.53 1.24 -15.99 
 25 0.04 0.16 0.00 -17.56 1.10 -16.26 
 30 0.14 0.10 0.01 -17.57 0.97 -16.45 
 35 0.04 0.07 0.01 -17.58 0.87 -16.59 
 40 0.04 0.06 0.01 -17.59 0.78 -16.70 
 50 0.03 0.04 0.02 -17.60 0.64 -16.86 
 55 0.04 0.04 0.02 -17.60 0.69 -16.82 
 60 0.03 0.02 0.02 -17.61 0.56 -16.97 
 65 0.03 0.04 0.02 -17.62 0.51 -17.01 
 70 0.03 0.03 0.03 -17.62 0.49 -17.05 
 75 0.03 0.01 0.03 -17.61 0.46 -17.08 
HEDP 10 0.01 0.43 0.02 -15.67 -10.93 -26.14 
 15 0.00 -0.15 0.15 -12.81 -1.70 -14.51 
 20 0.00 -0.12 0.14 -13.02 -1.11 -14.11 
 25 0.03 0.17 0.01 -14.70 -0.15 -14.64 
 30 0.03 0.01 0.17 -13.23 0.21 -12.82 
 35 0.03 0.01 0.17 -13.25 0.19 -12.85 
 40 0.03 0.02 0.16 -13.27 0.18 -12.88 
 50 0.02 0.13 -0.01 -14.96 0.14 -14.68 
 55 -0.03 -0.02 0.44 -13.64 -0.03 -12.88 
 60 0.02 0.15 -0.02 -15.96 0.71 -15.09 
  
 
 
Ligand ε /ε0 Components of the strain energy 
/kcal mol-1 
∆Es 
/kcal mol-1 
 
 
Bond 
stretching 
Angle 
bending 
Torsion Non-
bonded 
Electro-
statics 
 
 65 0.02 0.15 -0.02 -15.96 0.66 -15.15 
 70 0.02 0.15 -0.02 -15.96 0.62 -15.19 
 75 0.02 0.15 -0.02 -15.97 0.58 -15.24 
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4.3. Interactions of the bisphosphonates with the hydroxyapatite surface  
 
4.3.1. Interactions of the mono-protonated bisphosphonates with the hydroxyapatite 
surface 
The energy of interaction between the bisphosphonate ligands studied and hydroxyapatite is 
dominated by non-bonded interactions (Table 12, note all energies are the mean of 20 
independent minimisations).  
 
 
Figure 16: Graphical representation showing the dependence of the total energy of the minimised structure 
on the relative permittivity 
E∆ / kcal mol-1 
relative permittivity / ε o 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
4.3.1.1. Interactions with the (001) face of hydroxyapatite 
All five bisphosphonate ligands that were studied interacted in a similar fashion with the (001) 
face.  The two phosphonate groups pointed downwards towards the surface (Figure 17A), usually 
close to one of the surface Ca2+ ions (Table 13), and with the bulk of the ligand positioned in a 
surface trigonal cavity that is lined with phosphate groups (Figure 17B).  In addition, in HEDP 
the OH substituent on the α carbon, and the protonated OH group of the phosphonate form 
hydrogen bonds with the phosphate groups lining the surface trigonal cavity (Figure 17C). For 
APD and alendronate the Cα hydroxyl forms an internal hydrogen bond with one of the oxygen 
atoms of a phosphonate group.   
 
The magnitude of the interaction energy increases with the molecular volume of the ligand, 
reaching a maximum with alendronate, and then decreasing significantly for neridronate (Table 
12 and Figure 18). The side chains of APD and alendronate align with the (001) surface, which 
increases the non-bonded interactions (Figure 17D). In neridronate, however, the side-chain folds 
on itself and does not interact significantly with the surface of the mineral thus reducing the non-
bonded interactions (Figure 17E). 
 
Table 12: Interaction of bisphosphonates with hydroxyapatite: distances between oxygen atoms 
of phosphonates and the nearest calcium ions on the 001 face of hydroxyapatite 
 
ligand O••••Ca2+ distances /Å a 
 First Ca2+ ion  Second Ca2+ ion  
 First Phosphonate  Second 
Phosphonate 
Second Phosphonate 
MDP 3.09 ± 0.06 3.24 ± 0.10  3.11 ± 0.12  
HEDP 3.71 ± 0.02 2.950 ± 0.003 3.11 ± 0.10  4.34 ± 0.02 
APD 3.47 ± 0.01    (5.1 ± 0.2) 
Neridronate 3.23 ± 0.01 3.43 ± 0.02 4.45 ± 0.10  4.12 ± 0.10 
Alendronate 3.03 ± 0.05    3.04 ± 0.09  
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Figure 17: Representations of the interaction of the bisphosphonates with the (001) face of 
hydroxyapatite (Represented by: A-C HEDP and D-E alendronate) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E 
Figure 18:  Dependence of the interaction energy of five bisphosphonate ligands    
and the (001) face of hydroxyapatite on the molecular volume of the 
ligand 
  
 
 
4.3.1.2. Interactions with the (010) face of hydroxyapatite 
There were two principal conformations adopted by bisphosphonates on the (010) surface.  In 
both the molecules dock in the cavity that runs alongside the rows of hydroxyl and phosphate 
groups that define the surface (Figure 19A).  In the first conformation (termed conform A in 
Table 12), found for MDP and about 40% of the structures of alendronate on the (010) face, both 
phosphonate groups interact with the surface (Figure 19B).  One of the phosphonate groups 
inserts well into the surface such that one of its oxygen atom interacts with three calcium ions in 
the plane below the surface plane. The second phosphonate group is within van der Waals 
interaction of two Ca2+ from the neighbouring row.  In the second conformation (conform B in 
Table 12), adopted by the majority of ligands, only one of the phosphonate groups interacts with 
the surface (Figure 19C). All of its oxygen atoms are in van der Waals contact with three surface 
Ca2+ ions and two surface phosphate groups. The Cα side chain is in contact with the surface, 
while the second phosphonate group points towards the solution.   
 
Since in conform A the Cα side chain has little interaction with hydroxyapatite, the interaction 
energy is virtually independent of the structure of the bisphosphonate (-17.5 ± 1.0 kcal mol-1 for 
MDP, and -17.0 ± 1.0 kcal mol-1 for alendronate).  In conform B, the interaction energy increases 
with the size of the side chain (HEDP -15.9 ± 0.2; APD -18.0 ± 1.4; and alendronate -19.2 ± 0.7 
kcal mol-1) but decreases for neridronate (-17.8 ± 2.5 kcal mol-1), as was seen on the (001) face.  
The reason for this is the formation of a hydrogen bond between the amino group and the 
phosphonate group that is pointed away from the mineral surface, which prevents a complete 
interaction of the Cα side chain with hydroxyapatite. 
 
A 
  
 
 
 
 
 
Figure 19:  Representations of the interactions of the two conformations A and B adopted by the 
bisphosphonates when interacting with the (010) surface of hydroxyapatite 
(represented by HEDP) 
 
4.3.1.3. Interactions with (100) face of hydroxyapatite 
As for the interactions with the (010) face of hydroxyapatite, two conformations were seen for 
the interactions on the (100) face (Figures 20A and B).  As the structures of the (010) and (100) 
crystal were similar in nature, with both containing rows of phosphate groups aligned with 
hydroxyl and calcium rows, the interactions seen on the two faces are similar.  Similarly to the 
interactions with the (010), the bisphosphonate aligned within the cavity between these rows.  
The only difference between the two faces is that the cavity in which the bisphosphonate aligns is 
along the b axis rather than along axis c (Figure 20A).   
 
B 
C 
  
 
 
In the first conformation (termed conform A in Table 12), only one of the phosphonate groups 
pointed towards the surface and the Cα side chain interacted with the surface while in the second 
conformation (conform B), the Cα side chain interacted strongly with the surface and both 
phosphonate groups pointed away from the surface towards the solution.  The former 
conformation, which is the more common, is also energetically more favourable (Table 12).  The 
magnitude of the interaction is virtually insensitive to the nature of the side chain (∆Es = -16.3 ± 
0.7 kcal mol-1) and is over 6 kcal mol-1 more important than the average interaction energy for 
the second conformation (10 ± 2 kcal mol-1). 
 
 
 
 
Figure 20: Representations of the interactions of the two conformations A (represented by 
alendronate) and B (represented by HEDP) adopted by the bisphosphonates when 
interacting with the (100) surface of hydroxyapatite 
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4.3.2. Interactions of the di-protonated bisphosphonates with the hydroxyapatite surface 
From the available acid dissociation constants (Appendix Table A3) it is clear that nitrogen-
containing bisphosphonates exist both as mono- and di-protonated species at pH = 7.6 (Figure 
21) with the dominant species being the deprotonated ligand.  Thus it was necessary to examine 
whether addition of another proton to APD, alendronate and neridronate had any significant 
effect on the structure of their interaction with hydroxyapatite. 
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Figure 21: Species distribution for APD (A), alendronate (B) and neridronate (C). 
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4.3.2.1. Interactions with the (001) face of hydroxyapatite 
The interactions on the (001) surface are very similar to those found for mono-protonated APD 
and alendronate but very different for neridronate (Figure 22).   For all three ligands, the ligand 
was located in the surface trigonal cavity with both phosphonates and the side chain interacting 
with the surface, thus the magnitude of the stabilization energy increased as the chain size 
increased with neridronate having the highest (Table 14, Figure 24).   
 
A calcium ion is in close contact with one oxygen atom from each of the phosphonate groups, 
whilst at least one hydrogen atom from a protonated phosphonate is hydrogen-bonded to a 
phosphate ion on the hydroxyapatite surface.  A hydrogen bond is also present between the 
proton of the Cα hydroxyl group and an oxygen atom from one phosphonate group (Figure 23). 
 
Figure 22:  Representation of the interaction between the (001) surface of hydroxyapatite and 
neridronate, [H2L2-]. 
 
Figure 23:  Representation of the hydrogen bond present in the di-protonated bisphosphonates 
when interacting with the (001) surface (represented by neridronate). 
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Figure 24: Graphical representation showing that as the length of the Cα chain increases so the 
interaction energy increases 
 
4.3.2.2. Interactions with the (010) face of hydroxyapatite 
Two conformations are seen for the interactions with the (010) surface.  In conformation A (seen 
for alendronate and neridronate only) both phosphonate groups point downwards onto the 
surface, while in conformation B (seen for all three ligands) only one phosphonate interacts with 
the surface. In both, the Cα hydroxyl group points away from the surface while the amine chain 
interacts with the surface hydroxide ions.   
 
In conformation A, the ligand is aligned within the cavity formed by the chain of hydroxyl 
groups and the chain of phosphate ions.  A calcium ion is in contact with an oxygen atom from 
each of the phosphonate groups.  There are further interactions between the phosphonate groups 
and the calcium ions in the layer beneath the surface layer. 
 
In conformation B the ligand lies above the chains of hydroxide and calcium ions while the 
interacting phosphonate lies within the surface cavity.  All its oxygen atoms are in close contact 
with three calcium ions on the surface.  Conformation A is energetically more favourable than 
conformation B (Table 14).  For conformation A (Figure 25A) the magnitude of the interaction 
increases with the size of the side-chain but the converse is true for conformation B (Figure 25B) 
because, as the chain length increases, the chain becomes too long to preserve an interaction 
between the amino group and the surface hydroxide ions. 
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Figure 25: The interaction of the two conformations A and B of alendronate with the (010) 
surface of hydroxyapatite 
 
4.3.2.3. Interactions with the (100) face of hydroxyapatite 
One principal conformation occurs on the (100) surface, although APD does adopt a second 
conformation (Table 14, Figure 26).  In the principal conformation, the ligand aligns in the cavity 
that runs along the a-axis and only one of the phosphonate groups points towards the surface.  An 
oxygen atom from this phosphonate interacts with a Ca2+ ion.  The Cα side chain aligns parallel 
to the surface along the a-axis thus the interaction energy increases monotonically with the length 
of the side-chain (Table 14). 
 
For conformation B of APD both phosphonate groups interact with the surface but the Cα chain 
points away from the surface.  Since both the phosphonate groups interact with the surface the 
stabilization energy is greater than for conformation A. 
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Figure 26: Representation of the interaction of conformation A (represented by alendronate) and 
B (represented by APD) of the bisphosphonate with the (100) surface of 
hydroxyapatite. 
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Chapter 4: Conclusion 
 
It has been shown that our augmentation to the generalised AMBER force field, GAFF, and 
which we have called WitsGAFF Force Field models interaction well in both a vacuum 
environment and a synthetic aqueous environment (by using a relative permittivity of 78ε0), with 
experimental and modelled bond lengths and angles within the required specifications [50].  The 
minimised structures usually adopt the gauche or anti conformation.  By using simulated 
annealing it was determined that these local minimum structures are equivalent to the global 
minimum structure.   
 
The principal aim of this project was to start determining a mechanism as to how the 
bisphosphonates treat bone cancer.  Molecular modelling has shown the affinity of the crystalline 
bone apatite (hydroxyapatite) is different when different substituients are present on the central 
carbon.  In addition the affinity and the nature of the interactions are different on different faces 
of hydroxyapatite with the interactions on the (001) face being the least complex of the 
interactions.  The interactions on all the faces were dominated by electrostatic interactions 
between the phosphonate groups and amine group on the bisphosphonate with the phosphate and 
calcium ions in the hydroxyapatite.  As we only looked at the interactions with a synthetic bone 
equivalent there is still much work to be done to determine the exact mechanism, as natural 
occurring bone is a great deal more complex. 
 
 
 
 
 
 
 
 
  
 
 
Chapter 5: Future Work 
 
As the field of bone cancer research is extremely large it is impossible to suggest all the possible 
research opportunities with the bisphosphonates.  In my opinion the next important step is to try 
to synthesize additional bisphosphonates with varying substituents on the central carbon to 
determine if our force field parameter files WitsGAFF model them correctly.   
 
More research is needed into the interactions of the bisphosphonates on other faces of 
hydroxyapatite and on bone. 
 
Once our force field has been tested it is necessary to try to add other elements to Wits-GAFF.  
Initially we should try to add small metal anions as our body contains so many metal ions that it 
will be important to see how in the presence of a metal the ligand will bind and how this will 
affect the affinity of the bisphosphonate to hydroxyapatite.  The next step will be the inclusion of 
the radionuclides into the force field. 
 
In addition it is necessary that this research be complemented with results from other scientific 
techniques such as potentiometry, protein NMR and in vivo studies. 
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Section 1: Supplementary tables in the Appendix 
Table A1: The structures of known bisphosphonates obtained from the CSD, and their CSD   
………….reference codes 
 
CSD Structure Ref Code 
 
AHIJUW [65] 
 
BEKBOJ[66] 
 
BEKBUP [66] 
  
 
 
CSD Structure Ref Code 
 
CAEADP [67] 
CAKKEF [68] 
 
CAVKUF [69] 
 
DEZGAQ [70] 
  
 
 
CSD Structure Ref Code 
 
EFAMIH [71] 
 
EMIGIQ [72] 
 
ETHDPH [73] 
 
ETHDPH01 [74] 
  
 
 
CSD Structure Ref Code 
 
FEZLUR [75] 
 
FEZMAY [75] 
 
FIRCAK [75] 
 
FURCAW [76] 
  
 
CSD Structure Ref Code 
 
GOWZEX [77] 
 
HOWCAX [78] 
 
IGUMAY [79] 
 
IGUMEC [79] 
  
 
 
CSD Structure Ref Code 
 
JAGXUL [72] 
 
JAGYAS [72] 
 
JOTVET [80] 
 
KAGREQ [81] 
  
 
 
CSD Structure Ref Code 
 
KIBLOW [82] 
 
KOGSAA [83] 
 
KOJGUL [84] 
 
LIYTOC [85] 
CSD Structure Ref Code 
  
 
 
LIYTOC01 [85] 
 
LIYTOC02 [85] 
 
MEYDPA [86] 
 
MEYDPA11 [87] 
  
 
 
CSD Structure Ref Code 
 
MODGUH [74] 
 
MOFVOS [88] 
 
MUPTIA [89] 
 
MUQDIL [90] 
  
 
 
CSD Structure Ref Code 
 
MUSLUH [91] 
 
NAMDPC01 [69] 
 
NODSEL [92] 
 
PAWTUC [93] 
  
 
 
CSD Structure Ref Code 
 
QURXOQ [94] 
 
QURXUW [94] 
 
QURYAD [94] 
 
RIMGUP [95] 
  
 
 
CSD Structure Ref Code 
 
SATHIE [96] 
 
SATHIE01 [97] 
 
SATHIE02 [98] 
 
SHEDPH [16] 
  
 
CSD Structure Ref Code 
 
SOPSAR [99] 
 
SOPSEV [99] 
 
VEYJAK [98] 
 
VUYTUE [100] 
  
 
 
CSD Structure Ref Code 
 
WURPOO [101] 
 
WURXEM [102] 
 
XOBMIK [103] 
 
XOBMIK01 [104] 
  
 
 
CSD Structure Ref Code 
 
XOSGER [105] 
 
XOSGIV [105] 
 
ZARJAD [106] 
 
ZARJEH [106] 
  
 
 
CSD Structure Ref Code 
 
ZARJIL [106] 
 
Table A2: The structures and ref codes of structures obtained from the CSD excluded from the 
modelling 
 
Structure  Ref Code Reason for Exclusion 
 
JOTVIX [80] Hyperchem[42] has 
insufficient parameters 
for bromine 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Table A3: Comparison of bond lengths and bond angles obtained using the structures 
 obtained from simulated annealing 
 Number of protons Average  Standard 
Parameter 0 1 2 3 4 5   deviation 
Bond lengths/ Å 
                
P5-C3 1.835 1.836 1.837 1.836 1.837 1.839 1.837 0.001 
P5-O 1.554 1.554 1.540 1.518 1.481 1.482 1.521 0.034 
P5-OH n/a n/a 1.627 1.628 1.628 1.591 1.618 0.018 
OH-HO 0.974 0.975 0.974 0.976 0.974 0.979 0.975 0.002 
C3-OH 1.436 1.437 1.435 1.436 1.438 1.436 1.436 0.001 
C3-C3 1.551 1.551 1.551 1.550 1.550 1.551 1.551 0.000 
C3-H 1.093 1.092 1.092 1.092 1.093 1.093 1.092 0.000 
C3-NH 1.507 1.508 1.508 1.507 1.508 1.508 1.508 0.001 
NH-HN 1.033 1.033 1.033 1.033 1.033 1.033 1.033 0.000 
                  
Bond angles/ degrees 
                
P5-C3-P5 113.9 114.4 114.2 113.6 114.1 115.3 114.3 0.6 
O-P5-C3 107.6 107.6 108.5 109.3 110.8 111.7 109.3 1.7 
OH-P5-C3 n/a n/a 104.1 104.6 104.5 105.6 104.7 0.7 
O-P5-O 111.1 111.1 111.5 112.7 111.2 n/a 111.5 0.7 
O-P5-OH n/a n/a 110.0 110.2 112.5 112.6 111.3 1.4 
OH-P5-OH n/a n/a n/a n/a 105.2 108.0 106.6 2.0 
HO-OH-P5 n/a n/a 110.5 107.7 110.3 104.9 108.3 2.6 
OH-C3-P5 104.0 104.7 103.9 104.0 105.1 104.3 104.3 0.5 
HO-OH-C3 110.0 110.3 109.8 109.9 110.3 110.2 110.1 0.2 
C3-C3-P5 112.7 112.3 112.7 113.0 111.9 112.1 112.5 0.4 
C3-C3-OH 108.5 107.6 108.6 108.3 108.1 107.8 108.1 0.4 
C3-C3-C3 113.6 113.6 113.6 113.8 113.6 113.6 113.6 0.1 
H-C3-C3 109.3 109.3 109.3 109.3 109.3 109.3 109.3 0.0 
H-C3-H 107.8 107.8 107.8 107.8 107.8 107.9 107.8 0.0 
C3-C3-NH 110.5 110.7 110.7 109.9 110.7 110.7 110.5 0.3 
H-C3-NH 108.0 108.0 108.0 108.0 108.0 108.0 108.0 0.0 
C3-NH-HN 110.0 110.4 110.4 110.4 110.4 110.5 110.4 0.2 
HN-NH-HN 108.1 108.5 108.5 108.5 108.5 108.5 108.4 0.2 
         
All values are an average of ten measurements 
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Figure A1:  Distribution of torsional angles for the torsion –O-P- C-P 
 
Figure A2:  Distribution of torsional angles for the torsion HO-P-C-P 
Figure A3:  Distribution of torsional angles for the torsion -O-P-C-X (where X is any substituent) 
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Figure A5:  Charge distribution for atom type P5 
 
Figure A4:  Distribution of torsional angles for the torsion OH-P-C-X (where X is any substituent) 
 
Figure A6:  Charge distribution for atom type C3 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
Figure A8: Charge distribution for atom type OH 
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Figure A7: Charge distribution for atom type O 
       Figure A9: Charge distribution for atom type HO 
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A2. An example of an .ent file 
HEADER    CSD ENTRY AHIJUW 
COMPND    UNNAMED 
AUTHOR    GENERATED BY CONQUEST 
CRYST1    6.666    6.676   15.571  84.08  82.80  85.78 P -1   2 
ATOM      1  N1  UNK 0   1       7.949   1.985   1.638  1.00  0.00 
ATOM      2  H1  UNK 0   1       8.400   2.130   2.362  1.00  0.00 
ATOM      3  C1  UNK 0   1       8.433   1.596   0.465  1.00  0.00 
ATOM      4  H2  UNK 0   1       9.355   1.490   0.266  1.00  0.00 
ATOM      5  N2  UNK 0   1       7.429   1.458  -0.374  1.00  0.00 
ATOM      6  H3  UNK 0   1       7.478   1.179  -1.183  1.00  0.00 
ATOM      7  C2  UNK 0   1       6.260   1.760   0.274  1.00  0.00 
ATOM      8  H4  UNK 0   1       5.420   1.745  -0.132  1.00  0.00 
ATOM      9  C3  UNK 0   1       6.572   2.078   1.551  1.00  0.00 
ATOM     10  C4  UNK 0   1       5.678   2.429   2.693  1.00  0.00 
ATOM     11  H5  UNK 0   1       6.176   2.883   3.419  1.00  0.00 
ATOM     12  H6  UNK 0   1       5.014   3.036   2.305  1.00  0.00 
ATOM     13  C5  UNK 0   1       4.922   1.201   3.287  1.00  0.00 
ATOM     14 Na1  UNK 0   1       6.547   2.065   6.798  1.00  0.00 
ATOM     15  O1  UNK 0   1       4.200   0.615   2.203  1.00  0.00 
ATOM     16  H7  UNK 0   1       3.713  -0.031   2.468  1.00  0.00 
ATOM     17  O2  UNK 0   1       7.096   0.782   4.842  1.00  0.00 
ATOM     18  O3  UNK 0   1       6.779  -0.724   2.795  1.00  0.00 
ATOM     19  O4  UNK 0   1       5.318  -1.011   4.829  1.00  0.00 
ATOM     20  H8  UNK 0   1       5.788  -1.697   4.897  1.00  0.00 
ATOM     21  O5  UNK 0   1       2.790   2.787   3.796  1.00  0.00 
ATOM     22  O6  UNK 0   1       4.425   2.391   5.727  1.00  0.00 
ATOM     23  O7  UNK 0   1       2.908   0.545   4.925  1.00  0.00 
ATOM     24  H9  UNK 0   1       2.086   0.634   4.895  1.00  0.00 
ATOM     25  O8  UNK 0   1       9.059   1.646   7.747  1.00  0.00 
ATOM     26  H10 UNK 0   1       9.379   1.947   8.474  1.00  0.00 
ATOM     27  H11 UNK 0   1       9.658   1.907   7.216  1.00  0.00 
ATOM     28  O9  UNK 0   1       5.776   3.190   8.767  1.00  0.00 
ATOM     29  H12 UNK 0   1       5.549   2.626   9.312  1.00  0.00 
ATOM     30  H13 UNK 0   1       5.395   3.898   8.964  1.00  0.00 
  
 
ATOM     31  O10 UNK 0   1       7.618   3.832   5.591  1.00  0.00 
ATOM     32  H14 UNK 0   1       8.196   4.213   6.050  1.00  0.00 
ATOM     33  H15 UNK 0   1       8.043   3.475   4.949  1.00  0.00 
ATOM     34  O11 UNK 0   1       9.308  -1.548   2.285  1.00  0.00 
ATOM     35  H16 UNK 0   1       8.514  -1.274   2.353  1.00  0.00 
ATOM     36  H17 UNK 0   1       9.338  -2.210   2.794  1.00  0.00 
ATOM     37  P1  UNK 0   1       6.162   0.009   3.947  1.00  0.00 
ATOM     38  P2  UNK 0   1       3.718   1.828   4.531  1.00  0.00 
CONECT    1    2    3    9 
CONECT    2    1 
CONECT    3    1    4    5 
CONECT    4    3 
CONECT    5    3    6    7 
CONECT    6    5 
CONECT    7    5    8    9 
CONECT    8    7 
CONECT    9    1    7   10 
CONECT   10    9   11   12   13 
CONECT   11   10 
CONECT   12   10 
CONECT   13   10   15   37   38 
CONECT   14    0 
CONECT   15   13   16 
CONECT   16   15 
CONECT   17   37 
CONECT   18   37 
CONECT   19   20   37 
CONECT   20   19 
CONECT   21   38 
CONECT   22   38 
CONECT   23   24   38 
CONECT   24   23 
CONECT   25   26   27 
CONECT   26   25 
CONECT   27   25 
  
 
CONECT   28   29   30 
CONECT   29   28 
CONECT   30   28 
CONECT   31   32   33 
CONECT   32   31 
CONECT   33   31 
CONECT   34   35   36 
CONECT   35   34 
CONECT   36   34 
CONECT   37   13   17   18   19 
CONECT   38   13   21   22   23 
MASTER        0    0    0    0    0    0    0    0   38    0   38    0 
END 
 
  
 
A3. An example of a .hin file 
forcefield mm+ 
sys 0 0 1 
view 40 0.18557 55.75 15.75 1 0 0 0 1 0 0 0 1 -5.872 -1.0015 -59.814 
seed -1111 
mol 1 
res 1 UNK 1 - 0 
atom 1 N1 N OW - 0 7.949 1.985 1.638 3 2 s 3 s 9 s 
atom 2 H1 H HO - 0 8.4 2.13 2.362 1 1 s 
atom 3 C1 C B3 - 0 8.433 1.596 0.465 3 1 s 4 s 5 s 
atom 4 H2 H H - 0 9.355 1.49 0.266 1 3 s 
atom 5 N2 N OW - 0 7.429 1.458 -0.374 3 3 s 6 s 7 s 
atom 6 H3 H HO - 0 7.478 1.179 -1.183 1 5 s 
atom 7 C2 C B3 - 0 6.26 1.76 0.274 3 5 s 8 s 9 s 
atom 8 H4 H H - 0 5.42 1.745 -0.132 1 7 s 
atom 9 C3 C B3 - 0 6.572 2.078 1.551 3 1 s 7 s 10 s 
atom 10 C4 C C4 - 0 5.678 2.429 2.693 4 9 s 11 s 12 s 13 s 
atom 11 H5 H H - 0 6.176 2.883 3.419 1 10 s 
atom 12 H6 H H - 0 5.014 3.036 2.305 1 10 s 
atom 13 C5 C C4 - 0 4.922 1.201 3.287 4 10 s 14 s 24 s 25 s 
atom 14 O1 O O2 - 0 4.2 0.615 2.203 2 13 s 15 s 
atom 15 H7 H SI - 0 3.713 -0.031 2.468 1 14 s 
atom 16 O2 O ** - 0 7.096 0.782 4.842 1 24 s 
atom 17 O3 O ** - 0 6.779 -0.724 2.795 1 24 s 
atom 18 O4 O O2 - 0 5.318 -1.011 4.829 2 19 s 24 s 
atom 19 H8 H SI - 0 5.788 -1.697 4.897 1 18 s 
atom 20 O5 O ** - 0 2.79 2.787 3.796 1 25 s 
atom 21 O6 O ** - 0 4.425 2.391 5.727 1 25 s 
atom 22 O7 O O2 - 0 2.908 0.545 4.925 2 23 s 25 s 
atom 23 H9 H SI - 0 2.086 0.634 4.895 1 22 s 
atom 24 P1 P CP - 0 6.162 0.009 3.947 4 13 s 16 s 17 s 18 s 
atom 25 P2 P CP - 0 3.718 1.828 4.531 4 13 s 20 s 21 s 22 s 
endres 1 
endmol 1 
mol 2 
  
 
atom 1 NA1 Na ** - 0 6.547 2.065 6.798 0 
endmol 2 
mol 3 
atom 1 O8 O O2 - 0 9.059 1.646 7.747 2 2 s 3 s 
atom 2 H10 H SI - 0 9.379 1.947 8.474 1 1 s 
atom 3 H11 H SI - 0 9.658 1.907 7.216 1 1 s 
endmol 3 
mol 4 
atom 1 O9 O O2 - 0 5.776 3.19 8.767 2 2 s 3 s 
atom 2 H12 H SI - 0 5.549 2.626 9.312 1 1 s 
atom 3 H13 H SI - 0 5.395 3.898 8.964 1 1 s 
endmol 4 
mol 5 
atom 1 O10 O O2 - 0 7.618 3.832 5.591 2 2 s 3 s 
atom 2 H14 H SI - 0 8.196 4.213 6.05 1 1 s 
atom 3 H15 H SI - 0 8.043 3.475 4.949 1 1 s 
endmol 5 
mol 6 
atom 1 O11 O O2 - 0 9.308 -1.548 2.285 2 2 s 3 s 
atom 2 H16 H SI - 0 8.514 -1.274 2.353 1 1 s 
atom 3 H17 H SI - 0 9.338 -2.21 2.794 1 1 s 
endmol 6 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
A4: An example of an entry in a logfile 
HyperChem log start -- Wed Dec 27 13:44:56 2006. 
Geometry optimization, MolecularMechanics, molecule = C:\Documents and Settings\Di\My 
Documents\simplebps\3OH\BEKBOJ_x1.hin. 
mmplus 
PolakRibiere optimizer 
Invalid atom type for atom 4. 
Invalid atom type for atom 18. 
Invalid atom type for atom 19. 
Unknown torsion constant for 
atom(   1   2   3   5) 
type(**-C4-CP-**). 
Unknown torsion constant for 
atom(   1   2   3   5) 
type(**-**-**-**). 
Default parameters being used for torsions... 
Using default torsion constants 
V1 = 0.000000 
V2 = 0.000000  
A5: An example of the optimisation macro used to perform the minimisation 
Control-R Compute.Results 
    
Channel =OpenFile() 
  =IF(ISERROR(Channel)) 
  =    RETURN() 
  =END.IF() 
    
  =EXECUTE(Channel,"[query-response-has-tag(no)]") 
  =EXECUTE(Channel,"[file-format(hin)]") 
    
  =WHILE(NOT(ISBLANK(SELECTION()))) 
    
    
    
    
Command =EXECUTE(Channel,"[open-file(E:\HEDP_dynamics\"&SELECTION()&".hin)]") 
  =EXECUTE(Channel,"[optim-algorithm steepestdescents]") 
  =EXECUTE(Channel,"[optim-max-cycles=1000]") 
  =EXECUTE(Channel,"[do-optimization]") 
    
  =EXECUTE(Channel,"[optim-algorithm polakribiere]") 
  =EXECUTE(Channel,"[optim-max-cycles=1000]") 
  =EXECUTE(Channel,"[do-optimization]") 
  =SELECT("r[1]c") 
  =EXECUTE(Channel,"[write-file(E:\HEDP_dynamics\"&SELECTION()&".hin)]") 
    
  =SELECT("r[1]c") 
  =NEXT() 
  =TERMINATE(Channel) 
  =RETURN() 
  OpenFIle 
NewChan =INITIATE("HyperChem","System") 
  
=IF(ISERROR(NewChan)) 
  
=    IF(ISERROR(EXEC("d:\Program Files\Hypercube\HyperChem5\PROGRAM\chem.exe",1))) 
  =        RETURN(NewChan) 
  =    END.IF() 
  =    RETURN(INITIATE("HyperChem","System")) 
  =END.IF() 
  =RETURN(NewChan) 
 
A6: An example of the statistics macro used to collect the 
statistics data 
 
Control-R Compute.Results 
    
Channel =OpenFile() 
  =IF(ISERROR(Channel)) 
  =    RETURN() 
  =END.IF() 
 
 
 
 
 
   
    
  =EXECUTE(Channel,"[query-response-has-tag(no)]") 
  =EXECUTE(Channel,"[file-format(hin)]") 
    
  =WHILE(NOT(ISBLANK(SELECTION()))) 
    
    
   
   
Command =EXECUTE(Channel,"[open-file(C:\Hyper7\Data\simplebps\noOH\"&SELECTION()&".hin)]") 
 =EXECUTE(Channel,"[select-atom 1,1]") 
 =EXECUTE(Channel,"[select-atom 2,1]") 
 =FORMULA.ARRAY(REQUEST(Channel,"selection-value"),"r[1]c") 
 =EXECUTE(Channel,"[select-none]") 
 =SELECT("r[1]c") 
   
 =EXECUTE(Channel,"[select-atom 1,1]") 
 
=EXECUTE(Channel,"[select-atom 2,1]") 
 
=EXECUTE(Channel,"[select-atom 3,1]") 
 =FORMULA.ARRAY(REQUEST(Channel,"selection-value"),"r[1]c") 
 =EXECUTE(Channel,"[select-none]") 
 =SELECT("r[1]c") 
  
 =EXECUTE(Channel,"[select-atom 1,1]") 
 =EXECUTE(Channel,"[select-atom 2,1]") 
 =EXECUTE(Channel,"[select-atom 3,1]") 
 =EXECUTE(Channel,"[select-atom 11,1]") 
 =FORMULA.ARRAY(REQUEST(Channel,"selection-value"),"r[1]c") 
 =EXECUTE(Channel,"[select-none]") 
 =SELECT("r[1]c") 
 =EXECUTE(Channel,"[select-atom 4,1]") 
 =TERMINATE(Channel) 
 =RETURN() 
   
 OpenFIle 
NewChan =INITIATE("HyperChem","System") 
  =IF(ISERROR(NewChan)) 
 =    IF(ISERROR(EXEC("d:\Program Files\Hypercube\HyperChem5\PROGRAM\chem.exe",1))) 
 =        RETURN(NewChan) 
 =    END.IF() 
 =    RETURN(INITIATE("HyperChem","System")) 
 =END.IF() 
 =RETURN(NewChan) 
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